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This thesis discusses the design and production of peptides with side chain linkers that 
are intended to bind to the F3 domain of talin. The talin F3 domain was targeted as it is 
involved in the activation of integrin membrane proteins present in platelets. The over 
activation of these integrins can result in clotting within the blood vessels causing heart 
disease, however, current medication targeting integrin have negative side effects.  
The design and synthesis of short peptides based on the sequence of the β3 integrin tail 
that binds to the F3 domain of talin is presented. The binding affinity of peptides to the 
talin F3 domain was tested using NMR titrations to reveal the ideal location for the 
linker in the production of potential therapeutics which target integrin activation. Side 
chain linked peptides with high helical content have previously been shown to improve 
binding affinity. This drove investigation of side chain constrained peptides to increase 
their helical content, and thus, their binding affinity to talin F3 domain and cellular 
uptake.  
It is demonstrated that side chain linkers are effective in stabilising the helical structure 
of the short peptides. When incorporated in the β3 integrin sequence in specific 
locations, lactam linkers improved binding affinity of these peptides to the talin F3 
domain. Additionally, all-hydrocarbon and triazole linkers enhanced the peptide’s 
cellular uptake when compared to the native peptide of this sequence. The position and 
type of side chain linkers were investigated. The result of which showed that the 
position of the linker had a significant impact on the binding affinity to talin. The lactam 
linker between residues in positions 725 and 729 created a peptide (7) with the highest 
binding affinity. 
The cell penetration of peptides with different linker types was tested using NIH 3T3 
mouse cells, and HEK298 cells. A number of side chain linkers were tested with the 
triazole linker producing the most α-helical peptide, and the all-hydrocarbon linker 
producing peptides with the greatest cellular uptake. 
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1.1 Protein-Protein Interactions  
Protein-protein interactions play a central role in all biological processes, mediating 
molecular events that define life, growth, reproduction, ageing, disease and death1. The 
structure of a protein is determined by its three-dimensional structure, which arises 
through highly ordered folding of the polypeptide backbone. An understanding of 
protein structure and function with regards to the modulation of protein-protein 
interactions has the potential to i) facilitate the development of a better understanding 
of biological systems by providing tools to study complex biological interactions; ii) 
provide novel approaches for diagnostics of health and disease; iii) most importantly, 
provide a basis for new molecular therapeutics to fight disease. 
 
1.2 Secondary Structure 
Protein secondary structure, as defined by the ordered conformational arrangement of 
amino acids in localised regions of a polypeptide or protein, plays a key role in protein-
protein interactions2. The α-helix together with the β-sheet account for over 60% of the 
predominant structure at the interface of protein-protein interactions2. The structure 
of a protein can be described by the set of dihedral angles (Figure 1-1) phi (φ) and psi 
(ψ), which define the spatial orientation of the peptide backbone and the presence of 
specific hydrogen bonds between backbone carbonyl and amide functional groups.  
 
Almost half a century ago Ramachandran, Sasisekharan, and Ramakrishnan identified 
that the energy landscape of a blocked peptide unit can be mapped in two dimensions3. 
The Ramachandran plot (Figure 1-1) demonstrated that steric clashes alone eliminate 
¾ of φ, ψ- space. Regions free from steric clashes are the ‘allowed’ regions, and are 








i -1 i  i +1 Phi dihedral angle Psi dihedral angle 
φ ψ 
Figure 1-1: Top: ‘i’ is a single residue within a peptide chain where R is the 
amino acid side chain. Connection via amide bond to the adjacent residue 
toward the N-terminal i-1 is highlighted in blue, while the residue toward the 
C-terminal i+1 is highlighted in orange. Dihedral angles phi (φ) and psi (Ψ) are 
indicated on the residue in the i position. Bottom: Ramachandran plot of the 
steric energies of interaction as a function of the φ and angles Ψ first 
developed by Ramachandran and Sasisekharan (1968) to represent the 
sterically allowed conformations of a polypeptide chain. The space occupied 
by geometry of certain secondary structures defined by their phi and psi angles 
(blue), and disallowed regions (white). (Adapted from Van Holde et.al12) 
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1.2.1 α-Helix 
The α-helix, first described by Linus Pauling4, is the most common secondary structure 
found in proteins, and often forms fundamental recognition elements in protein-
protein interactions2. α-Helices are observed in almost 40% of natural polypeptides5, 
and form compact rod like structures with 3.6 amino acids per turn, with a length of 5.4 
Å (Figure 1-2B) and a radius, not including side chains, of 2.3 Å (Figure 1-2D). The 
average length of helical domains in proteins is relatively short, spanning two to three 
helical turns (8-12 residues)6. The backbone arrangement of the α-helix places the i, i+4, 
i+7 and i+11 side chains on the same face of the folded structure (Figure 1-2C). The 
principal geometry for the α-helix is ϕ = -57° and ψ = -47°, with hydrogen bonds 
between the backbone of carbonyl (C=O) and amine (NH) groups of the i and i+4 
residues. All of the backbone amide groups of an α-helix are involved in intra-chain 
hydrogen bonds, therefore the interactions of helices with other peptide domains or 







Figure 1-2: Depictions of α-helical structure. A: ribbon. B: 
backbone (carbon grey, nitrogen blue, oxygen red) indicating 
hydrogen bonding between NH of the i and the C=O of the i+4 
residues. C: end view of α-helix with alanine side chains 
indicating the i, i+4, i+7 and i+11 side chains in green, D: end 







A B C 
D 




310-Helices are significantly less common than α-helices, however they still play 
important roles in native peptide structure7. 310-Helices are often found as an extension 
of α-helices, in loops, and as connectors between β-sheets. A 310-helix is tighter than 
the α-helix, with dihedral angles of ϕ = -74° and ψ = -4°. Whereas α-helices display 
hydrogen bonds between the i and i+4 residues, hydrogen bonding in 310-helices occur 
between the i and i+3 residues (Figure 1-3). The backbone arrangement of a 310-helix 
places side chains of the i, i+3 and i+6 residues on the same face of the helix (Figure 
1-3).  
 
1.2.3 β-Sheets and Turns 
A β-sheet is the second most common secondary structure in proteins, and together 
with the α-helix account for over 60% of the predominant structure at the interface of 
protein-protein interactions2. Hydrogen bonding between β-strands results in self-
Figure 1-3: Depictions of 310-helical structure. Left: 
ribbon. Middle: backbone (carbon grey, nitrogen blue, 
oxygen red) indicating hydrogen bonding between NH of 
the i and the C=O of the i+3 residues. Right: end view of 
310-helix (top) with alanine side chains indicating the i, 
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association to give β-sheet secondary structure, which adopts either parallel (Figure 
1-4A) or antiparallel (Figure 1-4B) twisted pleated arrangements8.  
 
β-Turns represent sites where proteins reverse their overall chain direction. These 
structures are also known as reverse turns or hairpin turns and are the most common 
turn structure. These turn structures consist of four residues stabilised by hydrogen 
bonding between i and i+3 residues9 (Figure 1-5). Dihedral angles ϕ and ψ of i+1 and i+2 
residues are used to classify the type of β-turn. 
 
 
Figure 1-4: A) Ribbon representation of parallel (left, PDB 2B1L) and antiparallel (right, 2B1L) 
β-sheet arrangement. B) Structural arrangement of residues, indicating hydrogen bonding 
interactions between strands (dashed lines) in parallel (left) and antiparallel (right) β-sheet. 
Figure 1-5:  Ribbon representation of β-turn (circled, left), and 
structural representation (right) showing hydrogen bonding 
interactions (orange lines) between i and i+3 residues.  
A B 
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1.3 Techniques for the Characterisation of Secondary Structure 
Identifying the structural elements of protein interfaces is important for designing 
modulators of protein-protein interactions. Many techniques can be used to identify 
secondary structure within peptides and proteins, either in solution or in their 
crystalline state. Characterisation of secondary structure in solution is often performed 
using circular dichroism (CD), and nuclear magnetic resonance (NMR) spectroscopy. CD 
spectroscopy gives an indication of the percentage of secondary structure in peptides 
and proteins. NMR spectroscopy allows identification of the presence, and location of 
secondary structure.  
1.3.1 Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectroscopy produces characteristic spectra for different types 
of secondary structure and can be used to estimate the proportion of secondary 
structure present in a peptide when in solution. The major chromophore in a peptide 
or protein is the amide group, and the asymmetric secondary structures formed by 
polypeptides give rise to distinct CD spectra (Figure 1-6). A negative minima between 
215-230 nm, commonly observed for α-helices and β-sheets, is attributed to n → π* 
transition10. A positive maximum at 190 nm and negative minimum at 208 nm 
characterise the structure as α-helix rather than β-sheet. Absorbance’s at 190 nm, and 
208 nm arise from excitation splitting of the NV1 transition. The well-defined geometry 
of the α-helix results in the NV1 transition being split by the electric dipole transition 
moments among amides11. The ratio of ellipticity at θ208 to θ220 gives an indication of 
the type of helical structure. A θ208 /θ222 ratio of 0.9 is indicative of α-helical structure, 
and greater than 1 is indicative of a coiled coil structure. A 310-helix can be identified in 
CD spectroscopy by a θ208 /θ222 ratio of less than 0.47.  
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1.3.2 Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy allows identification of secondary 
structure in peptides, and small proteins (<35-40kDa) in solution. Amino acids have 
characteristic resonances resulting from the protons on the amine (NH), α carbon (Hα), 
and the side chains, identified in Figure 1-7. Scalar coupling constants and chemical 
shifts are commonly used to identify secondary structure within polypeptides. In α-
helical structures scalar coupling between the amide and alpha protons of greater than 
6 Hz (3JNHCHα < 6 Hz), and up-field shifts for the alpha proton (δ(Hα)) relative to random 
coil values are normally observed12. Nuclear Overhauser effect spectroscopy (NOESY) 
(or rotating frame Overhauser effect spectroscopy (ROESY) for short peptides) identifies 
short inter-proton distances (<5 Å) allowing for identification of sequential connectivity, 
through intra-residue NH-NH (dNN) and NH-CH (dαN, dβN etc.) cross peaks of nuclei in 
close proximity (Figure 1-7). For helical structure, non-sequential medium range 
dαN(i,i+4), dαN(i,i+3) and dαβ(i,i+3) NOEs are indicative of α-helical structure (Figure 1-7). 
Presence of dαN(i,i+4) versus weak dαN(i,i+2) NOE’s indicates α-helicity rather than 310-
helicity or turn conformations. NOESY spectra indicate the presence of 310-helical 
structure by clear dαN(i,i+2) NOE’s, dαN(i,i+3) dαβ(i,i+3) NOE’s13, 14. 
Figure 1-6: CD spectra for random coil (orange), β-sheet (green) 
and α-helix (blue).  
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1.4 Modulating Protein-Protein Interactions 
Where proteins contain deep hydrophobic pockets for binding small-molecule 
substrates (Figure 1-8A), protein-protein interfaces are often very large polar surfaces, 
with only shallow ligand-binding hydrophobic clefts (Figure 1-8B). The competitive 
inhibition of protein-protein interactions thus requires a molecule to make 
discontinuous, non-covalent contacts over a much larger surface area and with a less 
defined shape compared to a conventional substrate-binding cavity15. In the past, many 
protein-protein interactions were thought to be “undruggable”, due to the challenges 
 β-sheet α-helix 310-helix 
dαN (i, i+4) 
dαβ (i, i+3) 
dαN (i, i+3) 
dNN (i, i+2) 
dαN (i, i+2) 
dNN 
dαN 
1  2 3 4  5 6 1  2  3 4  5 6 7 1  2  3 4 5 6 
3JHNα(Hz) 9  9  9  9  9  9 4  4  4  4   4  4  4 4  4   4  4  4  4 
Figure 1-7: A) NOE interactions between i and i+1 residues. 
α, β and γ carbon are labelled, protons  bound correspond 
to labelled carbon, i.e. Hα is highlighted by a red circle. B) 
Summary diagram of NOE interactions in common 
secondary structures.  
A 
B 
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associated with identifying effective approaches to develop compounds that modulate 
or inhibit these interactions.  
 
Figure 1-9 displays an example of small molecules interaction with a protein binding site 
and a protein-protein interaction. Figure 1-9A is an image from the X-ray crystal 
structure of a small molecule substrate, biotinyl-5’AMP, bound to the biotin protein 
ligase of Staphylococcus aureus16. The natural substrate adopts a U-conformation on 
binding to the hydrophobic active site, which is partially enclosed by a loop structure 
shown in blue, protecting the substrate from the aqueous environment. In contrast 
Figure 1-9B is an image from the average NMR solution structure of β3 integrin 
cytoplasmic tail interacting with talin17. This interaction occurs over a large surface with 
few hydrophobic pockets and is characteristic of protein-protein interactions.  
Figure 1-8: A) Schematic depiction of enzyme substrate 
binding and protein-protein interaction, identifying the 
required inhibitor design for each of these interactions. 
(Adapted from Wilson et.al15) 
A 
B 
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The past decade has seen significant progress in the development of small molecules, 
that obey the rule of 518, as inhibitors of protein-protein interactions1,19,20. Nutlin-2 is 
an example of a small molecule identified by high through-put screening. This 
compound competitively inhibits p53-hDM2 interaction (Figure 1-10A), and leads to cell 
cycle arrest, apoptosis and inhibition of tumour growth in mice21. Biologically inspired 
approaches have also been developed to target protein-protein interactions, e.g. 
therapeutic antibodies such as Efalizumab that binds to the αLβ2 integrin receptor22 
(Figure 1-10B). It is evident that small molecules, and large biologically-derived 
compounds can be produced to target protein-protein interactions, and compounds 
obtained through both these strategies have reached clinical trials. Compounds and 
scaffolds applicable to a broad range of topographies have been designed to target 
protein-protein interaction identified through screening of chemical libraries15 and 
rational design. Collectively these compounds result in a heterogeneous class of 
compounds known as peptidomimetics23.  
 
Figure 1-9: A) Biotnyl-5’-AMP (coloured by element) bound to biotin protein ligase of 
Staphylococcus Aureus (ribbon: green/blue, surface: green)16; B) β3 integrin cytoplasmic tail 
(ribbon: red) interacting with talin (surface: yellow), a critical interaction required for platelet 
activation17. 
A B 




The design of inhibitors for conventional targets are often based endogenous ligands. A 
similar approach can be applied to protein interfaces using a section of the protein 
which binds to the interface. This sequence-based approach has limitation as native 
peptide sequences derived from proteins are not ideal as drugs due to their poor 
bioavailability, and low stability under physiological conditions. Stable isolated 
peptides, with less than 15 amino acids, rarely adopt defined conformations in isolation, 
and loss of structure diminishes the ability of the peptide to bind the target interface.  
Protein-protein interactions are also critically dependent on a few residues at the 
interface, which make a dominant contribution to the free energy of binding. The key 
residues that contribute the majority of the binding affinity are known as ‘hot-spot’ 
residues. The concept of hot-spot residues was first identified, by Wells and Clackson, 
in the course of alanine mutagenesis studies involving the interaction of human growth 
hormone with its receptor24.  
Approaches to broadly target protein-protein interactions have endeavoured to 
overcome the issues associated with native peptides by stabilising peptide structure, i) 
using synthetic modification within the peptide sequence such as side chain linkers 
(1.5), ii) and by developing scaffolds mimicking secondary structure topology, to which 
‘hot spot’ residues can be inserted. For example, cyclotides are backbone cyclised 
Figure 1-10: A) Nutlin-2 (small molecule coloured by element) bound to p53-hDM2 (blue)22; B) 
Structure of Efalizumab Fab complex (blue) with LFA-1, αL 1 domain (orange)23.  
A B 
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peptides containing a cysteine knot motif built from six conserved cysteine residues 
(Figure 1-1125). The high sequence variability, stability, and cell penetrating properties 
of cyclotides make them potential scaffolds, to be used to graft known active peptides26.  
 
 
1.5 Helix Stabilisation: Side Chain Covalently Constrained α-Helices 
The average helical domain within a protein spans only 8-12 residues and as such, short 
helices can be developed to participate in selective interactions with biomolecules. 
However, such peptides rarely retain their structural conformation once isolated from 
the native sequence, and therefore their associated binding affinity for a target is often 
diminished. The pre-organisation of peptide residues can restore and even enhance the 
binding affinity relative to the native interaction. The development of numerous mimics 
of this important structural topology has been inspired by the prevalence of α-helical 
secondary structure in peptides and proteins. Approaches used to generate helical 
secondary structure topology can be divided into three general categories: helix 
stabilisation, helix foldamers, and helical surface mimetics27-33. Strategies for helix 
stabilisation are detailed below. 
Figure 1-11: Left: NMR solution structure of circular protein, MCoTI-II, a 
cyclotide, a novel trypsin inhibitor isolated from Momordica 
cochinchinensis, a member of the Cucurbitaceae plant family25. Right: 
Schematic of cyclic peptide indicating links between cysteine residues 
which result in a cysteine knot structure.  
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A highly promising approach for helix stabilisation is the incorporation of a linker 
between amino acids designed to nucleate α-helical structure. Side chain constraints 
are obtained by covalently linking the side chains of amino acids on the same face of 
the helix, i.e. i and i+4, or i and i+7. This stabilises α-helical motifs in biologically 
important polypeptides34. Such constrained α-helical peptides have been shown to 
enhance resistance to proteolysis, improve affinity for the target protein interface, and 
increase cell permeability relative to their unconstrained counterpart 35, 36.  
There are numerous methodologies for covalently linking side chains to give a helical 
side chain constrained peptide37, 38. The most extensively investigated constraint 
strategies include lactam bridges39 and all-hydrocarbon constraints40. Developed more 
recently, triazole41-43 and perfluorobenzyl36 constraint strategies have shown promise 
in nucleating helicity and enhancing cell permeability respectively (Figure 1-12).  
 
1.5.1 Lactam Bridge Constraints 
Lactam bridge linkers have received much attention since first being reported to 
stabilise α-helical structure in a segment of human growth hormone releasing factor 
(GRF), by Felix and co-workers in 198844. A lactam bridge linking i and i+4 residues was 
introduced by coupling the side chains of lysine and aspartic acid. The peptide 
analogues with lactam bridge linkers were found to have increased helical content 
compared to the unconstrained peptide analogue. These analogues were also shown to 
be highly potent, potentially due to stabilisation of a preferred bioactive conformation. 
Optimisation studies of lactam bridge linkers investigated the linker length, and amide 
Figure 1-12: Structures indicating backbone constrained into helical conformation by A: lactam 
linker, B: all-hydrocarbon linker, C: triazole linker, D: perfluorobenzyl linker. 
A B C D 
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position within the bridge for inducing helicity 39,45. For linkers between i and i+4 
residues, a 7 atom linker was identified as optimal for inducing α-helicity.  This linker 
was formed by coupling of lysine and aspartic acid side-chains. Shorter linkers 
destabilised α-helical structure, while longer linkers only stabilised helical secondary 
structures in some peptides. The order in which lysine and aspartic acid are 
incorporated into the peptide sequence also influences helical content. The linkers 
formed between lysine in the ith position, and aspartic acid in the i+4th position (KD 
linker, Figure 1-13)39 produced greater helix stabilisation than the alternative linker 
between aspartic acid (i) and lysine (i+4) (DK linker), rationalised to be due to a sterically 
preferred positioning of the amide bond in relationship to the peptide backbone. 
Lactam bridge linkers produced between glutamic acid and lysine were optimised with 
glutamic acid in the ith position and lysine in i+4th position (EK)45.  
 
Lactam bridge linkers have been reported to increase the stability of glucagon-like 
peptide-1 (GLP-1) to enzyme degradation46, and have been used to determine the 
preferred structural conformation of secretin analogues in the development of effective 
receptor antagonists for the secretin receptor47. Modified peptides containing two and 
three non-overlapping lactam bridge linkers displayed increased helicity, while retaining 
significant flexibility. The introduction of overlapping lactam bridges has resulted in 
stable, regular α-helical structures that were highly resistant to thermal degradation.  
Figure 1-13: Schematic of the formation of a KD lactam bridge linker. 
The lactam bridge is formed using an amide coupling reaction, linking 
lysine an aspartic acid side chains of residues incorporated in i, and i+4 
positions respectively. 
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1.5.2 Constraints introduced by Ring Closing Metathesis 
Blackwell and Grubbs48 were the first to design helix inducing linkers to peptides using 
olefin ring closing metathesis (RCM). Peptides were designed with two O-allyl serine 
residues, or homo O-allyl serine residues in the i and i+4 positions of a short 
hydrophobic peptide sequence48. CD of the resulting peptides suggest neither linker 
enhanced α-helical content, however NMR and crystallography identified a significant 
increase in rigidity of the native structure49. Based on this work, Verdine and co-
workers50 developed an all-hydrocarbon linker produced via RCM of α-methylated 
amino acids bearing olefin side-chains. An 8 atom linker between i and i+4 residues with 
S configuration (Figure 1-14) was highly effective at increasing α-helical content of 
peptides derived from Bcl-2 homology domain51. Additionally, incorporation of the all-
hydrocarbon linker increased cellular uptake of peptides through an energy dependent 
endocytosis mechanism51, 52.  
 
All-hydrocarbon linkers have been used to enhance the binding of peptides that are 
known to modulate the activity of several biological targets involved in a variety of 
human diseases, including cancer51, 53-60, diabetes61, human immunodeficiency virus 
(HIV)35, 62-64, and atherosclerosis65. Notably, a peptide derived from the transcriptional 
co-activator protein, incorporating an all-hydrocarbon linker, directly disrupted 
formation of the Notch transcription factor complex59, inhibiting leukemic progression 
in a murine model of T-cell acute lymphoblastic leukemia. Baek and co-workers 
reported a peptide (SAH-p53-8) with an all-hydrocarbon linker that interacted with the 
Figure 1-14: Schematic of the formation of an all-hydrocarbon linker 
using ring closing metathesis, linking i, and i+4 residues containing 
olefin groups.  
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protein surface, augmenting the binding interface66 (Figure 1-15). This study introduced 
the possibility of designing peptide linkers, which can interact with the target protein to 
improve binding affinity.  
 
1.5.3 Triazole Linker  
An α-helical turn was shown to be stabilised in cyclopeptides containing 1,4-
disubstituted [1,2,3] triazolyl-linkers generated though copper(I)-mediated Huisgen 1,3-
dipolar cycloaddition (the ‘click’ reaction) reactions67. Cantel et al. accessed these 
triazole linkers by reaction of the side chain azido and alkynyl moieties of azido-L-
norleucine [L-Nle (εN3)] and L-propargylglycine (L-Pra) in i and i+4 positions (Figure 1-16). 
Triazole constraints were used to produce analogues of the peptide inhibitor for 
parathyroid hormone-related peptide67. CD and NMR studies revealed that the triazole 
linked peptides displayed some variation in backbone structure when compared to that 
of the lactam bridged derivative, however both linkers organised residues within the 
helical turn in the same spatial orientation. Scrima41 and subsequently Kawamoto43 
optimised triazole linkers between i and i+4 residues. Both studies revealed an optimum 
linker length of 8 atoms (a total of 5 CH2 flanking the triazole ring) for inducing helicity. 
Azido-L-norleucine [L-Nle(εN3)] and D-propargylglycine (D-Pra) at i and i+4 positions were 
found to produce the optimum linkers for enhancing helicity and affinity of analogues 
Figure 1-15: Left: X-ray crystal structure of all-hydrocarbon linked peptide, 
SAH-p53-8. Hydrocarbon linker in yellow, backbone in blue, oxygen of 
carbonyl groups displayed in red. (Right) X-ray crystal structure of SAH-p53-
8 bound to E3 ubiquitin protein ligase63.  
C h a p t e r  1   | 18 
 
derived from a helical segment of B-cell CLL/lymphoma 9 (BCL9) for β-catenin43. Linkers 
derived from D-propargylglycine (D-Pra) were only marginally better than the L-
propargylglycine (L-Pra), and subsequent analysis of alanine rich pentapeptides, suggest 
that α-helicity was enhanced to a greater extent in peptides with linkers derived from L 
-propargylglycine (L-Pra)68, and there is variation in the resulting helical structured of 
these linked peptides, which may be dependent on the sequence of the peptide. 
 
Kawamoto also developed peptides containing two triazole bridges43. The peptides with 
two triazole bridges had a higher percentage of helical structure in CD studies, 
compared to peptides with a single constraint. The peptides were also highly potent for 
targeting β-catenin, a protein that plays an important role in several types of cancer. 
Incorporation of two linkers also improved protease stability relative to the linear 
peptide sequence. Kawamoto proposed that the generation of peptides containing two 
triazole linkers may be possible in scenarios where incorporating two hydrocarbon 
linkers could lead to significant amounts of mixed linkers (various combinations of side 
chains forming linkers)43. Jacobsen and co-workers applied the triazole side chain 
constraint strategy to stabilising 310-helical structure42. Constraints were formed 
between side chains of azido-L-norvaline and O-propynyl-L-serine in the i and i+3 
positions for an aminoisobutyric acid (Aib) rich sequence42. NMR, and X-ray diffraction 
were used to analyse the peptide structure, and results suggest the constrained peptide 
adopted a more ‘ideal’ 310-helix. 
Figure 1-16: Schematic of the formation of a triazole linker using ‘click’ 
reaction, linking L-norleucine (εN3), and L-propargylglycine residues i, 
and i+4 positions. 
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1.5.4 Cysteine Perfluoroarylation 
 
Spokoyny and co-workers developed the cysteine arylation platform as a mild synthetic 
method for cyclisation of unprotected peptides with cysteine residues in i and i+4 
positions36. The linker is introduced by nucleophilic aromatic substitution of 
hexafluorobenzene (Figure 1-17) and decafluorobiphenyl species, to give two different 
perfluoroaryl linkers. These perfluoroaryl links were incorporated into short peptides 
derived from the glycosaminoglycan (Gag) polyprotein, which is involved in HIV. The 
cellular uptake of the perfluoroaryl linked peptide analogues was comparable to that of 
the all-hydrocarbon bridge analogue previously investigated35. CD of both single ring 
and double ring species were complicated as the linkers gave rise to an absorbance 
maximum at 222 nm. α-Helical content was estimated by subtracting the absorbance of 
the cysteine disubstituted ring species from CD spectra of the constrained peptides. The 
single ring species had an estimated increase in helicity of 40%, while the double ring 
species displayed an increase of 20%.  
 
1.6 Chemical Synthesis of Peptides 
The original approach to peptide synthesis was to carry out reactions in solution69. After 
each synthetic step, the product needed to be isolated and purified. The solution phase 
peptide synthesis strategy is therefore only amenable to short peptide sequences. 
Convergent strategies were developed linking blocks of amino acids together to access 
longer peptide sequences. The development of solid phase peptide synthesis (SPPS) was 
the breakthrough that enabled widespread access to synthetic peptide sequences, 
Figure 1-17: Schematic of the formation of a perfluorobenzyl linker 
using nucleophilic aromatic substitution reaction, linking cysteine 
residues i, and i+4 position by reaction with hexafluorobenzene. 
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without the need for extended isolation or purification procedures after each step. 
Comparison of solution phase and solid phase techniques, in Table 1-1, briefly 
summarises the benefits and disadvantages of each method.  
 
Table 1-1: Comparison of chemical synthetic methods of peptide synthesis, solution 






1.6.1 Solid Phase Peptide Synthesis 
Solid phase peptide synthesis (SPPS) involves sequential addition of amino acids to an 
insoluble polymeric support (resin). The peptide chain is grown from C-terminus to N-
terminus by addition of appropriately protected amino acids. Amino acids are 
temporarily protected with Nα-protecting groups. These groups are removed once the 
amino acid is linked to the resin, so addition of the subsequent amino acid can occur. 
Functional groups of reactive side chains are protected with ‘semi-permanent’ 
protecting groups, which generally remain through the entire synthesis, and are usually 
removed during or after the peptide’s cleavage from the resin (Figure 1-18).  
There are two common Nα-protecting group strategies employed during solid phase 
peptide synthesis, acid labile tert-butyloxycarbonyl (Boc) protecting group strategy, or 
the base labile 9-fluorenylmethoxycarbonyl (Fmoc) protecting group strategy. The Fmoc 
  Method 
  Solution Phase Solid Phase 
No. amino acids Less than 10 10-40 
Strategy Segment/convergent Stepwise 
Cost of raw material Low Higher 
Solubility problems Frequent/serious Occasional/minor 
Work-up required Maximal Minimal 
Toxic solvent waste Moderate High 
Chemistry Highly specialised Simple/general 
Automation No Yes 
Purity Excellent Acceptable 
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protecting group strategy reduces issues associated with sequential acid treatments, 
while also requiring milder conditions for the removal of the peptide from the solid 
support. The Fmoc protecting group strategy is often favoured over the Boc protecting 
group strategy, due to milder conditions for peptide removal, and the Boc strategy is 
generally reserved for the synthesis of non-natural peptide analogues which are base 
sensitive.  
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Figure 1-18: General schematic showing the steps involved in solid phase peptide 
synthesis. Peptides are assembled on a solid support by attachment through the linker 
which makes up the resin. Repetition of coupling and deprotection steps result in 
elongation of the peptide chain. Once the peptide is complete it is cleaved from the resin. 
During cleavage the side chain, protecting groups are often removed. 
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1.6.2 9-Fluorenylmethoxycarbonyl (Fmoc) Protecting Group Strategy 
Solid phase peptide synthesis using the Fmoc protecting group strategy involves the 
assembly of amino acids with Fmoc Nα-protection, and acid labile side chain protecting 
groups71. The process of peptide assembly involves two major steps, coupling and 
deprotection (Figure 1-18). The Fmoc group is removed by addition of piperidine to give 
a free amine. Resin tests can be utilised to establish that the reactions involved in 
coupling and de-protection steps have reached completion72-74. Once the full length 
peptide has been synthesised it is cleaved from the resin, the conditions required for 
cleavage often result in the side chain protecting groups being removed. Solid phase 
peptide synthesis can be performed manually or using automation. The development 
of automated microwave peptide synthesis has allowed rapid assembly of peptide 
sequences using heating by microwave radiation, to improve the efficiency of coupling 
and deprotection steps75.  
1.7 Defining a relevant target 
1.7.1 Coronary Heart Disease 
Coronary heart disease accounts for the largest single cause of death in the world76, and 
as such, new tools for treatment of heart disease are in high demand. Improved 
treatments for disease can reduce fatalities and improve quality of life. The application 
of methodologies that target protein-protein interactions provides the potential to 
target novel pathways. 
Coronary heart disease presents in two clinical forms, myocardial infarction, and angina. 
Acute myocardial infarction (a heart attack) and angina are caused by obstructions to 
the flow of blood to the heart, usually caused by coronary artery thrombosis. 
Thrombosis formation results from a disease known as atherosclerosis, which is the 
chronic inflammation of arteries, developed over decades in response to the biological 
effects of risk factors. As a result of atherosclerosis, plaques are formed within arteries, 
which can limit blood flow (causing stable angina). When physical disruption (rupture) 
of the plaque occurs, this exposes pro-coagulant material within the core of the plaque 
to coagulation proteins on platelets, triggering thrombosis77.  
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1.7.1.1 The Role of Platelets  
Platelets play a central role in the coagulation cascade, recognised to potentiate clot 
formation and inflammation78. Platelets circulate through the vessels in an inactive 
state, which is supported by healthy endothelium. Rupture or erosion of the fibrous cap, 
which covers plaques, results in platelet activation and aggregation, the formation of 
fibrin rich thrombi, and the partial or total occlusion of the coronary artery. Plaque 
rupture or erosion results in the release of tissue factor and exposure of sub-endothelial 
collagen and von Willebrand factor (vWF). Circulating platelets adhere to the exposed 
collagen and vWF and undergo cytoskeletal rearrangement, generation of 
cyclooxygenase I (COX-I) dependent thromboxane A2 (TxA2), and release the contents of 
stored granules including adenosine diphosphate (ADP). Interaction of thromboxane A2 
with the thromboxane A2 receptor and ADP with its receptor (P2Y12) initiates positive 
feedback activating additional platelets in a regional manner, and promoting the 
expression of additional αIIbβ3 integrin receptors which bind fibrinogen crosslinking 
platelets79 (Figure 1-19). 
 
Figure 1-19: Platelet activation, indicating key receptors, their substrates, and key 
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Current therapeutics target key pathways of platelet activation include preventing 
thromboxane A2 synthesis, ADP-mediated signalling, and integrin αIIbβ3 activation. The 
most common antiplatelet agents include aspirin, clopidogrel and integrin αIIbβ3 
antagonists80 (Figure 1-19). Patients have variable responses to all currently available 
therapeutics, consequently novel antiplatelet agents are being sought which over-come 
issues of currently available medication81-83, with bleeding (often gastrointestinal 
bleeding) potentially the most significant side effect84. 
1.7.1.2 Targeting αIIbβ3 Integrin  
Modulation of integrin αIIbβ3 activity using an antagonist is an extremely promising 
approach, due to the key role of αIIbβ3 in platelet aggregation, particularly as integrin 
αIIbβ3 is specific to platelets. Inhibitors of αIIbβ3 integrin approved by the FDA include 
an antibody fragment (abciximab), a cyclic peptide (eptifibatide) and a small molecule 
(tirofiban), which are all administered intravenously. Abciximab (c7E3 Fab) is a chimeric 
human-murine monoclonal antibody Fab (fragment antigen binding) fragment85. 
Eptifibatide is a cyclic heptapeptide containing mercaptopropionyl (MPA) and six amino 
acid residues (MPA, hArg, Arg, Gly, Asp, Trp, Pro and Cys)86. The peptide is cyclised by 
formation of an intra-chain disulfide bond between the cysteine and the 
mercaptopropionyl moieties (Figure 1-20A). Tirofiban is a tyrosine derived small 
molecule Arg-Gly-Asp (RGD) mimetic. Many integrins recognise the RGD sequences in 
their ligands87 (Figure 1-20B). The uses of current pharmacological inhibitors targeting 
αIIbβ3 integrin have unfortunately been limited, due to an associated increased 
likelihood of severe bleeding88, 89, and a lack of oral bioavailability. Attempts to develop 
oral antagonists for more convenient administration have been unsuccessful90. Never-
the-less, αIIbβ3 integrin antagonists have important benefits in the treatment of 
coronary heart disease, and are incorporated in treatment plans of many patients 
immediately after surgery85.  
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Structurally, integrins are made up of two subunits, α and β, each of which consist of a 
short cytoplasmic tail, a single transmembrane helix, and a large extracellular domain91 
(Figure 1-21). The large extracellular domain binds large protein ligands that can bridge 
platelets together (fibrinogen and von Willebrand factor), or modulate aggregation 
(vitronetin and fibronectin)92. Integrins are expressed on the surface of cells in a low 
affinity binding conformation, or inactive state. Activation of the integrin complex 
involves the transition from a low to a high affinity state for binding ligands. Once 
activated, the αIIbβ3 integrin extracellular domains extend and attach to circulating 
proteins, thereby initiating aggregation. Integrins are true receptors, involved in 
bidirectional signalling across the plasma membrane92, 93. Ligand binding to the 
extracellular domains is transduced to the cytoplasm to regulate intracellular activities, 
a process referred to as outside-in signalling. On the other hand, inside-out activation94, 
is stimulated within the cytoplasm when cells are activated, signalling integrin 
activation.  
 
Figure 1-20: A) Left, the structure of Eptifibatide, is a cyclic heptapeptide. Right: Eptifibatide 
bound to extracellular pocket of αIIbβ3 integrin. B) left, the structure of Tirofiban, a small 
molecule based on the Arg-Gly-Asp (RGD) sequence. Right: Tirofiban bound to extracellular 
pocket of αIIbβ3 integrin83. 
B 
A 
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Alternative methods for modulating αIIbβ3 integrin have the potential to overcome the 
issues associated with current therapeutics. All current pharmacologic inhibitors of 
αIIbβ3 integrin target the extracellular binding pocket to impaired platelet aggregation, 
but these compounds are associated with increased likelihood of severe bleeding88, 89, 
and lack oral bioavailability. The function of the αIIbβ3 integrin in platelet aggregation 
is dependent on its ability to undergo activation95 (Figure 1-21). Alternate methods of 
targeting αIIbβ3 integrin focusing on preventing activation, rather than directly binding 
to the extracellular pocket, may result in therapeutics which overcome issues with 
current drugs96. Investigation of modulators of the protein-protein interactions 
involved in αIIbβ3 integrin activation is therefore a promising avenue for the 
development of probes and possible novel therapeutics targeting platelet aggregation. 
  
Figure 1-21: Schematic depiction of the αIIbβ3 integrin membrane-spanning complex. Left: 
displays the receptor in its inactive conformation: Right: displays the activated state of αIIbβ3 
integrin indicating the α and β subunits, short cytoplasmic tail, a single transmembrane helix 
and a large extracellular domain. (Adapted from Shattil et al.91) 
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1.8 Overview of Thesis 
This thesis investigates the stabilisation of an α-helical conformation in peptides derived 
from the cytoplasmic tail of β3 integrin. Covalent side chain linkers, incorporated 
through linking side chains of i and i+4 residues, are used to stabilise α-helical 
conformation. Peptides are designed to prevent the activation of αIIbβ3 integrin 
through competitive binding to talin F3 domain. The synthetic peptides are prepared by 
solid phase peptide synthesis. The binding of peptide derivatives of the β3 integrin tail 
is investigated to determine the effect of linker location on affinity, and to determine 
the ideal location for linker incorporation. The effect of linker type on peptide helicity 
and cellular uptake is also studied to identify the effect of polarity and overall charge of 
peptides entering the cell.  
Chapter 2 is concerned with the design and synthesis of a panel of lactam linked 
peptides, which target talin by binding at the integrin-talin binding interface. The 
identification of hot spot residues from computational analysis is used to identify the 
integrin target sequence. The effect of linker location on helicity and structural 
characteristics is investigated using circular dichroism (CD) spectroscopy and nuclear 
magnetic resonance (NMR) spectroscopy. NMR titrations to determine binding affinity 
for talin will then be compared with structural information to determine the 
requirements determining the linker location to achieve the greatest binding affinity.  
Chapter 3 investigates the effect of linker type on the conformation and cellular uptake 
properties of linked peptides. The α-helical content of peptides derived from the β3 
integrin cytoplasmic tail with lactam, all-hydrocarbon and triazole linkers incorporated 
are to be compared using CD spectroscopy. Cellular uptake of these peptides are 
determined to facilitate direct comparison between different constraint strategies. The 
structural characteristics and cellular uptake of a perfluoroaryl linker will also be 
investigated using CD spectroscopy and confocal microscopy. Additionally, the effect of 
overall negative, neutral and positive charge of peptides on cellular uptake using all-
hydrocarbon linked peptides is investigated. 
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2.1 Integrin activation 
Modulation of the process by which αIIbβ3 integrin is activated presents as a promising 
target for the development of novel therapeutics for platelet aggregation1. Integrins are 
the main receptors that cells use to bind and respond to the extracellular matrix, and 
the regulation of integrin activation is important for a wide range of anchorage 
dependant cellular events. Activation of integrins is tightly regulated through inside-out 
signalling. The binding of a cytoskeletal protein, talin, to the β integrin cytoplasmic tail 
is the final step in the activation process2, 3. Talin binds to the β tail of integrin, causing 
separation of the cytoplasmic α and β tails, and activation4 (Figure 2-1Figure ).  
 
Talin is a 270 kDa protein, with an N-terminal globular head, and a C-terminal rod like 
tail. The rod like tail contains integrin, vinculin5 and actin6 binding sites, as well as 
binding sites for proteins involved in recruiting talin to the membrane to activate 
integrins7. Talins head contains an atypical FERM domain with the addition of an F0 
domain to F1, F2 and F3 domains, which adopt an extended structure8. The model 
emerging from studies is that the plasma membrane interactions are mediated via the 
Figure 2-1: Activation of integrin by talin binding the final step in 
the activation process. 
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F1, F2 and F3 subdomains9-11. The F3 domain binds the β3 integrin cytoplasmic tail over 
an extensive interface, which can be divided into two parts12-14, the membrane proximal 
(MP) region which interacts with the helical section of the β3 tail close to the cell 
membrane, and the membrane distal (MD) region which interacts with the relatively 
unstructured section of the β3 tail. Wegener and co-workers defined the structure of a 
complex between talin and the membrane-proximal integrin β3 cytoplasmic domain, 
using NMR spectroscopy15. NMR solution structures of talin F3 bound to a chimeric 
peptide comprised of the membrane proximal (MP) region of the β3 tail and C-terminal 
region of PIPKIγ are shown in Figure 2-2A. The chimeric peptide was used in this study 
as it displayed tighter binding to the talin F3 domain than the native peptide. 
Importantly mutagenesis studies revealed integrin activation could be markedly 
diminished with β3 integrin variants lacking key residues F(730) and F(727) in the 
cytoplasmic tail domain, but which retained the ability to bind talin. The first crystal 
structure of an authentic full length β integrin cytoplasmic tail (1B) bound to talin F2-F3 
domains (talin2 isoform)13 was subsequently reported by Anthis et al.4 (Figure 2-2B). 
This structural information provides a strong basis for the development of compounds 
which can modulate integrin activation.   
 
 
Figure 2-2: A: Averaged NMR solution structure of β3 bound talin F3 domain14, B: Crystal 
structure of 1B integrin bound to talin F2-F3 domains3. 
B A 
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2.2 Talin: A target for inhibiting integrin activation 
Initial investigations of the talin-integrin αIIbβ3 interaction determined that 
overexpression of talin head domain lead to activation of αIIbβ3 receptor16. Activation 
was found to be dependent on the presence of talin head domain, and integrin β3 tail. 
Petrich and co-workers performed mutation studies in mice to investigate the effect of 
disrupting interactions with the β3 tail1. All mice displayed pathological bleeding with 
complete loss of β3 tail. Less than 5% of mice displayed pathological bleeding due to 
mutation to the β3 tail that disrupted talin binding alone. These mice also received 
protection from microvascular thrombosis. In mice with a mutation disrupting the 
binding of both talin and other cytoplasmic proteins, microvascular thrombosis was 
prevented, however over 50% of mice displayed evidence of pathological bleeding. The 
study established αIIbβ3 integrin activation was dependent on interaction of talin with 
the β3 tail, in vivo. The results also suggest that pathological bleeding is associated with 
the degree of loss of integrin activity. Selectively disrupting the interaction between 
talin and the β3 integrin cytoplasmic tail in this study appeared to prevent thrombosis 
formation, with reduced risk of pathological bleeding.  
2.3 Helical constrained peptides derived from the β3 integrin cytoplasmic tail 
2.3.1 Optimisation of lactam linked peptides 
The initial objective of this study was to determine if peptides derived from the β3 tail 
would display high helicity once lactam linkers were incorporated at positions A and B. 
A panel of short peptides (shown in Table 2-1) with sequences derived from the helical 
section of MP region of the β3 tail, from H(722)-A(735), were synthesised using 
fluorenylmethyloxycarbonyl (Fmoc) solid phase peptide synthesis protocols17 (see 
chapter 4.2 for experimental details). The peptides were designed with C-terminal 
amide groups rather than the native carboxylic acid group as this is known to improve 
the stability of peptides to protease degradation18. Rink amide resin was selected for 
synthesis as it produces peptides with C-terminal amides upon cleavage.  
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Table 2-1: Peptide sequences of derived from the integrin β3 tail. 








The linear peptide β3MP(722-735) was synthesised using an automated microwave 
peptide synthesiser from R(734) to R(724). Manual coupling of the first amino acid to 
the resin resulted in higher purity of synthesised peptides, likely due to the resin 
undergoing a longer swelling time, and minimising incomplete couplings by monitoring 
the reaction with the TNBS test19 for free amines. The final amino acids, D(723) and 
H(722), were also coupled manually due to formation of aspartimide after treatment of 
D(723) with piperidine to remove the N-Fmoc protection. Aspartimide formation was 
avoided by addition of 1-hydroxybenzotriazole (HOBt) to the deprotection solution in 
manual synthesis.  
Lactam linked peptides 1-5 were synthesised manually from A(735) to D(723). The 
linkers were formed between the side chains of natural amino acids, lysine and aspartic 
acid or glutamic acid (Table 2-1, linked residues). Lysine residue side chains were 
protected with highly acid sensitive protecting groups, methoxytrityl (Mmt), and 2-
phyenyl isopropyl oxy (Opip) protecting groups for aspartic acid and glutamic acid20. The 
Fmoc protected peptides were then treated with aliquots of 2% TFA in DCM for 2 
minutes to selectively remove the acid labile Mmt, and Opip protection groups. 
Successful removal of protecting groups was indicated by the lack of yellow 
chromophore in the filtrate, produced by the presence of the Mmt group in solution.  
Peptide Sequence Linker Position 
β3MP(722-735) H-HDRKEFAKFEEERA-NH2 None 
1 H-HDRKEFAKFEEDRA-NH2 A 
2 H-HDRKEFAKFEEERA-NH2 A 
3 H-HDRKEFADFEEERA-NH2 B 
4 H-HDRDEFAKFEEERA-NH2 B 
5 H-HDREEFAKFEEERA-NH2 B 
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Conditions required for lactamisation were identified by trialling different coupling 
reagents, (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
(PyBOP), N,N′-diisopropylcarbodiimide (DIC), N,N′-dicyclohexylcarbodiimide (DCC), 
bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP) and N-
[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide (HATU). Reactions were 
performed in DMF under basic conditions, achieved by addition of DIPEA. The reaction 
times for cyclisation of 1 (Table 2-1) were compared after addition of DIC, DCC, PyBroP 
and HATU to resin samples respectively (Table 2-2). Cyclisation with PyBroP, DIC and 
DCC produced a positive result using the TNBS test for detecting the presence of free 
amine after 48 hrs. PyBOP resulted in a negative TNBS test after 18 hrs and HATU 
exhibited a negative TNBS test for free amines after 1 hr. This suggests that cyclisation 
was incomplete for all samples other than those treated with HATU and PyBOP, which 
was confirmed using low resolution mass spectroscopy. While HATU required the 
shortest coupling time of 1 hr, cyclisation of the peptide under these conditions did not 
always result in the desired lactam linked peptide, rather it produced both the desired 
cyclic peptide and a by-product. Mass spectrometry of the crude sample suggested the 
presence of two major ions, one corresponding to the mass of the desired cyclic peptide, 
and the other to the mass of the linear peptide with the addition of 99 amu; which 
corresponds to addition of a guanidine group to the lysine residue required for 
cyclisation of the peptide, a common impurity from SPPS21. Guanidine capping of an 
amine is a result of the reaction of an amine with HATU. A proposed mechanism for the 
addition of the guanidine group is illustrated in Figure 2-3. The concentration of HATU 
to free carboxylic acid groups, in this case determined by the moles of unprotected 
aspartic acid side chains, is critical to ensure that the reaction results in cyclisation rather 
than capping of the lysine amine. Optimisation of the cyclisation conditions for the 
coupling reaction using HATU was not found to be possible due to variations in the 
moles of carboxylic acid groups available. The variations in the number of moles of 
peptide present for an individual reaction were likely a result of the resin loading after 
the addition of the first amino acid, and in the amount of resin due to the removal of 
resin for TNBS testing. PyBOP was therefore deemed to be the coupling reagent of 
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choice for reproducible results, despite the long reaction time required for cyclisation, 
and additionally the reaction could be successfully monitored by the TNBS resin test.  
 
Table 2-2: Cyclisation conditions trialled using peptide 1 to determine most effective 
cyclisation reagent. 
Coupling reagent Time for cyclisation (hrs) Result of TNBS test 
PyBOP 18 Negative 
DIC 48 Positive 
DCC 48 Positive 
PyBroP 48 Positive 
HATU 1 Negative 
 
 
Peptides 1-5 were cyclised using optimised conditions identified from the trial reactions 
discussed above. The peptides were thus cyclised on treatment PyBOP, and DIPEA in 
DMF, for 18 hrs. Following cyclisation, the Fmoc group was removed on treatment with 
piperidine and the N-terminal histidine (His) residue was coupled using HATU as the 
coupling agent. Histidine was couped after cyclisation to prevent unintentional removal 




Figure 2-3: Mechanism for the addition of the guanidine group to a free amine, 
resulting in a by-product with an additional mass of 99 amu.  














Identification of the linker that would produce the peptide with the greatest helicity was 
determined through characterisation of the structure of peptides 1-5 using CD 
spectroscopy. Spectra were obtained of purified samples of the unconstrained 
β3MP(722-735) and linked peptides in phosphate buffer, at pH 6.5 (Figure 2-5), this was 
to ensure consistency with the conditions required for NMR titrations with the talin F3 
domain discussed later in this chapter. The ratio of absorbance minima at 222 nm and 
208 nm (θ222/θ208) obtained from the CD spectra (Table 2-3), and the position of the 
absorbance minima were used to identify the peptide with the greatest α-helical 
structure. Peptides displaying helical content have a θ222/θ208 of close to 1 and a 
minimum close to 208 nm. All linked peptides displayed spectra characteristic of α-
helical structure, while the unconstrained peptide lacked an absorbance minimum at 
222 nm, indicating that the linkers increased the structural content of the peptides.  
Figure 2-4: Scheme for the synthesis and cyclisation of lactam linked peptides 1-5 




Table 2-3: Peptides synthesised and analysed by CD spectroscopy.  
 
Comparison of the linker position, either positioned at site A or B, and linker residue 
combination, with lysine and aspartic acid, or glutamic acid in the i or i+4th position, was 
explored to determine the arrangement that produced the greatest helicity. The two 
different linker positions tested were position A and B (Table 2-1). The KD linker was 
tested in both positions A and B, peptides 1 and 3 respectively, which produced peptides 
with the greatest helical content. Peptide 1 displayed the greatest α-helical content of 
all tested peptides with a θ222/θ208 ratio of 0.7, and minima at 207 nm. The θ222/θ208 ratio 
for all other linked peptides were 0.44 or below, indicating the presence of 310 helicity, 








Linker Ratio (θ222/θ208) Minima (nm) 
β3MP(722-735) None - N/A 202 
1 A KD 0.75 207 
2 A KE 0.44 203 
3 B KD 0.35 203 
4 B DK 0.24 203 
5 B EK 0.26 202 























Figure 2-5: CD spectra of peptides β3MP(722-735) and 1-5 derived from the integrin β3 tail. 
(~25μM concentration, 10mM phosphate buffer, pH 6.5, 298K) 
β3MP(722-735) Peptide 1 
Peptide 2 Peptide 3 
Peptide 4 Peptide 5 
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The most suitable linker length was determined by comparison of linker residues in 
position A. Peptides 1 and 2 link the lysine and glutamic acid residues (KE) or lysine and 
aspartic acid residues (KD). The KD linker is one atom shorter in length than the KE linker. 
It was hypothesised that the KE linker in peptide 2, which replaces the potential 
electrostatic attraction between lysine and glutamic acid with a covalent bond, would 
enhance helicity as it conserves the peptides original sequence. The KE linker does 
appear to increase helical content, however replacing the glutamic acid with an aspartic 
acid residue, resulting in the shorter KD linker, in peptide 1, resulted in the peptide with 
the greater helical content.  
The results suggest that the optimum linker for enhancing α-helicity is between lysine 
and aspartic acid (KD), in the i and i+4 positions, which is in agreement with previous 
comparative studies for lactam bridged peptides22, 23. This linker was therefore chosen 
for use in further investigations.  
 
2.3.2 Design of linked peptide: sequence and linker position 
Compounds were designed to disrupt the talin-β3 integrin interaction, motivated by 
their potential application in preventing platelet aggregation. Peptides were developed 
to bind to talin and disrupt interaction with the β3 integrin cytoplasmic tail without 
disrupting any other known talin functions. The talin MP region was identified as the 
target region13, 24 (Figure 2-6), the β3 tail is its only known ligand. The β3 tail binds in a 
helical conformation at the MP region of talin, and therefore peptides were designed 
based on the native MP β3 tail sequence, with helical structure stabilised using a side 
chain constraint approach (See Chapter 1.5). 
 





A Robetta online alanine scan25 was performed on the NMR solution structure of talin 
F3 domain bound to chimeric β3 tail (PDB 2H7E). Energetically important residues at the 
protein-protein interface with a stabilising effect on ΔΔG of more than 1 kcal/mol were 
identified as hot-spot residues. Robetta successfully identified known hot spot residues 
within the MP region, F(727) and F(730). These residues had previously been 
determined to contribute significantly to binding from experimental alanine mutation 
studies 15,13 (Table ). The energy contribution of residue E(733) has not been reported, 
however perturbation of integrin ligand binding and integrin activation has been linked 
to mutation at this site26. The tryptophan residue W(739) between the MP region and 
Figure 2-6: A: Ribbon representation of averaged NMR solution structures showing talin F3 
domain (yellow) bound to chimeric β3 tail (red). Membrane proximal (MP, blue) and distal (MD, 
green) regions are circled14. B: Averaged NMR solution structure of talin F3 domain (yellow 
surface) bound to β3 tail (red ribbon) showing hotspot residues side chains. C: The native 
sequence of the β3 tail in one letter code. Above the sequence the MP region is indicated in 
blue and MD region in green. Below the sequence secondary structures identified by NMR and 
crystallography are shown. The grey regions are α-helical and buried in the membrane, blue is 
α-helical, and orange region was found to be 310 helical in the crystal structure of the 1B tail12, 
MD region of β3 integrin is relatively unstructured with a small region of β-sheet (orange) and 
a turn structure16 (green outline), the crystal structure of 1B tail is unstructured in the MD 
region. 
Membrane distal (MD) 
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the MD region was also identified by Robetta, which predicted it would have the 
greatest contribution to binding of all the residues in the chimeric β3 tail. The order of 
residue energy contribution identified by Robetta was in agreement with experimental 
results. In addition, D(723) was identified as a hotspot residue, while this is not 
predicted from either the computational alanine scan or experimental mutation studies, 
evidence of salt bridge formation with talin residue K(327) was identified in the crystal 
structure of the closely related integrin 1D bound to talin F2-F313.  
Table 2-4: Values of ΔΔG calculated by Robetta online alanine server, and 
experimentally determine values previously reported for ΔΔG of the full length 
β3 tail determined by mutation of residues to alanine and analysis of binding to 
talin F3 domain by NMR. 
Residue Computational alanine scan 
(ΔΔG kcal/mol)* 





E(733) 1.15 N/D 
W(739) 4.39 8 (1.9) 
*Determined from Robetta online alanine scanner 
#Determine from NMR binding analysis 15,13 
^Calculated from combine mutation of F(727) and F(730) to alanine 
 
The determination of hot-spot residues led to the identification of two target sequences 
from the β3 tail. The first target sequence from H(722) to A(735) (Figure 2-6 C), 
contained three of the four hot-spot residues identified, and incorporated residues from 
the helical MP region only. The second sequence extended to the start of the MD region: 
H(722) to W(739). Extending the sequence to the hot-spot residue W(739) allowed the 
incorporation of all four hot-spot residues, however extended past the helical region 
suggested by NMR solution structures (Figure 2-6).  
The locations of the side chain linkers were selected on the opposite side to the 
interaction interface between the β3 integrin tail and the talin F3 domain. The linker 
between side chains prevents these side chains from interactions with the protein 
interface. The linker may also alter the structures interacting at the binding interface as 
the linker runs between these residues. Linker locations were selected which would 
minimise the linker’s potential disruptive effects on binding of peptides to the talin F3 
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domain, while stabilising the helical region of the β3 tail. Figure 2-7 shows three 
positions for the location of the linker, B, C and D, which were identified that would not 
interfere with binding; site A replaced E(733) with the linker, and was selected to 
determine the effect of disrupting the interaction of E(733) with talin F3, as predicted 
by the Robetta scan (Table 2-4).  
 
2.3.3 Structure and affinity of linear β3-integrin peptide sequences  
Two linear peptides of different lengths, β3MP(722-735) and β3MP(722-739), were 
tested for their structure and affinity to the talin F3 domain. A shorter peptide would 
speed up synthesis but may sacrifice binding affinity. The shorter peptide β3MP(722-
735) tested consisted of 14 residues which comprised only the helical section of the 
peptide. A longer peptide of 18 residues, β3MP(722-739), was also tested which 
comprised both the helical section and an unstructured section of peptide which may 
increase affinity to the talin F3 domain. 
The 18-residue peptide, β3MP(722-739), was synthesized by standard Fmoc solid-phase 






Figure 2-7: Left, helical wheel diagram of the α-helical region of the β3 
integrin cytoplasmic tail, indicating location of constraints introduced 
by replacing residues with lysine and aspartic acid in the i and i+4th 
positions respectively. Right, image from the averaged NMR structure 
of the MP region bound to talin, with the structure of hotspot residues 
E(733), F(730), D(723), F(727) indicated by red squares. 
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addition of residues K(738)-R(724). With the first residue, tryptophan (W), and residues 
D(723) and H(722) coupled manually. The peptide was then removed from the resin and 
purified by semi-prep HPLC. Manual coupling of the final residues, D(723) and H(722), 
was used in order to prevent aspartimide formation, as previously discussed in the 
synthesis of β3MP(722-735). The 14-residue peptide, β3MP(722-735), was prepared as 
discussed in section 2.3.1.  
β3MP peptides were characterised using CD spectroscopy in order to determine the 
structure present in the linear peptide (Figure 2-8). Quantification of helicity was based 
on the molar ellipticity at λ = 222 nm27 (see chapter 4.1.2.2, equation 2). β3MP(722-735) 
did not display an absorption minimum at 222 nm, suggesting the structure of this 
peptide is predominately a random coil. In comparison, β3MP(722-739) gave a weak 
minimum at 222 nm which equates to a helical content of 23%. A calculated ratio of 
molar ellipticity ([θ]222/[θ]208) for β3MP(722-739) of 0.5 suggests that the structure may 
be a combination of α-helical, 310 helical structure, and random coil28.  
 
The binding affinity of linear peptides β3MP(722-735) and β3MP(722-739) for the talin 
F3 domain was determined using two dimensional 15N-1H heteronuclear single-quantum 
Figure 2-8: CD spectra of β3MP(722-735) and β3MP(722-739). 
(10mM phosphate buffer, pH 6.5, 298K) 
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correlation (HSQC) spectra by analysing the resonance shifts in the F3 talin domain upon 
peptide binding. All NMR spectra were obtained and analysed in collaboration with Dr 
Kate Wegener, who guided sample preparation and performed NMR spectroscopy and 
analysis. HSQC spectra of a solution containing 15N labelled talin F3 domain were 
recorded with increasing concentrations of each linear peptide β3MP(722-735) and 
β3MP(722-739). The binding affinity of β3MP(722-735) for the talin F3 domain was not 
determined as the peptide began to precipitate from solution before the required 
concentration for accurate determination of the dissociation constant (Kd) was reached. 
The binding affinity of β3MP(722-739) to talin F3 domain was determined to be 
5.4 ± 0.2mM (Chapter 4.2.12 Figure 4-12), with the pattern of talin F3 resonance shifts 
indicating the peptide was interacting with the talin F3 domain in a similar way to longer 
fragments of β3-integrin tail, or the chimeric β3-integrin/PIPKIγ peptide (Figure 2-9). 
The binding affinity of the longer linear peptide was in the millimolar range, as expected 
since the binding affinity of the full length β3 integrin tail to the talin F3 domain was 




Figure 2-9: Plot of maximum shift of talin F3 resonance peaks in HSQC spectra with (top: 
red) addition of a peptide corresponding to the membrane proximal region (bottom: blue) 
β3MP(722-739) peptide. The regions highlighted in blue refer to the residues affected by 
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2.3.4 Optimisation of constraint location using lactam bridged peptides  
The affinity of the short peptide, β3MP(722-735), for the talin F3 domain was expected 
to be lower than the β3MP(722-739). The low binding affinity of β3MP(722-739) of 
5.4 ± 0.2mM therefore prompted the use of this sequence spanning from H(722)-
W(739), rather than the shorter β3MP(722-735) sequence for the incorporation of 
lactam linkers. A panel of lactam bridged peptides (see Table 2-5) was designed based 
on the β3MP(722-739) sequence to determine the ideal location to nucleate helicity and 
enhance binding of peptides to the talin F3 domain. Lactam constraints were introduced 
by linking the side chains of lysine and aspartic acid residues in the i and i+4 positions. 
The covalent constraints were introduced in positions A, B, C and D (Table 2-5, Figure 
2-7). Positions were chosen so as to not interfere with hot spot residues, only position 
A would disrupt potential binding of E(733) recognised by the Robetta results as the 
weakest interaction of all the identified hotspot residues (refer to section 1.4.1).  
 
Table 2-5: Sequences, helical character, and affinity of β3 integrin cytoplasmic tail derived 
peptides 
Peptide Sequence Bridge 
position 
Helicity [θ]222/[θ]208 
β3MP(722-735) HDRKEFAKFEEERA N/A 0% 0 
β3MP(722-739) HDRKEFAKFEEERARAKW N/A 23% 0.55 
6 HRDKEFAK*FEED*RARAKW A 48% 0.81 
7 HRDK*EFAD*FEEERARAKW B 57% 0.76 
8 HDRKEFK*KFED*ERARAKW C 42% 0.77 
9 HDK*KEFD*KFEEERARAKW D 51% 0.75 
 
Peptides 6, 7, 8 and 9 were synthesised using Fmoc solid-phase peptide synthesis17. 
Residues from K(738) to the residue before those involved in the linker were coupled 
using an automated microwave peptide synthesiser, with all other residues coupled 
manually as the linker residues required lower concentrations and longer coupling 
times. The success of the coupling reactions were also monitored by resin tests and 
mass spectrometry to ensure coupling reactions reached completion before elongation 
was continued. Linkers were introduced at positions A – D (Figure 2-7) in peptides 6-9 
by incorporation of lysine and aspartic acid residues in the i, and i+4 positions indicated 
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by the bold resides in Table 2-5. These lysine and aspartic residues were incorporated 
during peptide synthesis with acid labile protecting groups’ methoxytrityl (Mmt) and 2-
phyenyl isopropyl oxy (2-PhiPr) respectively. This allowed selective removal of these 
side chain protecting groups while the peptide remained bound to the resin, which was 
achieved by consecutive additions of 1% TFA. Cyclisation was then achieved on resin 
with addition of PyBOP in DIPEA for 18 hrs using the optimised conditions previously 
describe for peptide 1 (see section 2.3.1), to produce cyclic peptide 6, 7, 8, and 9. 
Peptides were characterised using mass spectrometry to confirm cyclisation was 
successful, and their purity was confirmed by analytical HPLC. 
CD spectra of 6, 7, 8, and 9 revealed characteristic spectral features associated with α-
helical structure, specifically minima at 208 and 222 nm, as apparent in Figure 2-10. 
These linked peptides demonstrated helical stabilisation, with increased helical content 
of between 15 and 28% compared to the linear peptide β3MP(722-739) (Table 2-5). 












Figure 2-10: CD spectra for the linear and four lactam bridged peptides 
illustrating the effect of bridge and bridging position on helical content. 
(10mM phosphate buffer, pH 6.5, 298K) 
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Two dimensional 15N-HSQC spectra of the 15N labelled talin F3 domain, titrated with 
increasing amounts of peptides 6 – 9, were used to generate binding curves (Figure 
4-12) through observation of key residue shifts to determine Kd values (Table 2-6). The 
binding of β3MP(722-739), and peptides 6 - 9 resulted in a pattern of shifted talin 
resonances, comparable to those identified previously for the β3 integrin tail15 (Figure 
2-11). This suggests that peptides 6 – 9 bind to talin at the integrin binding site15. The 
Kd values determine the effect of bridge position on affinity of peptides for the talin F3 
domain (Table 2-6). The binding affinities of peptides 7 and 9 were calculated to be 
0.9 ± 0.02 and 2.7 ± 0.1 mM respectively, indicating improved binding affinity to that of 
the unconstrained β3MP(722-739) peptide which had a Kd of 5.4 ± 0.2 mM. A constraint 
at position B, peptide 7, gave rise to a 5-fold increase in binding affinity compared to 
β3MP(722-739), while position D, peptide 9, resulted in a more moderate increase in 
affinity. Constraints at positions A and C (6 and 8) resulted in a decrease in affinity 
compared to β3MP(722-739). The reduced affinity of 6 would lend support to the earlier 
Robetta scan results indicating contribution from E(733) to binding affinity for talin. 
However, the observed reduced affinity of 8 was unexpected, since the bridge does not 
interfere with the binding residues, suggesting that other factors needed to be 
considered for linker placement. These results prompted further structural analysis of 
the peptides to determine differences in the peptides structure that may explain the 
results for their binding affinities.  
 
Table 2-6: displays the Kd of linear peptides and lactam linked peptides for binding to the talin 
F3 domain. 
 
Peptide Linker position (mM) 
β3MP(722-735) none N/D 
β3MP(722-739) none 5.4 ± 0.2 
6 A 6.5 ± 0.3 
7 B 0.9 ± 0.02 
8 C 7.0 ± 0.4 
9 D 2.7 ± 0.1 
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2.3.5 Structural characterisation 
CD spectra of the lactam bridge peptides 6 – 9, show characteristic minima that provide 
compelling evidence that the lactam bridge enhances helical structure relative to 
β3MP(722-739), however this does not allow for detailed analysis of the structure of 
peptides at the atomic level. Thus 1H homo-nuclear NMR spectroscopy studies were 
performed on β3MP(722-739) and cyclic peptides 6-9 in order to better define the effect 
of linker position on structure. This allows the determination of medium and long-range 
NOEs, coupling constants, temperature dependence of amide chemical shifts, and α-
proton chemical shifts. Spectra were recorded for β3MP(722-739) and peptides 6-9 in 
PBS buffer (50mM phosphate, 100mM NaCl, pH 6.1) with 10% added D2O to more 
closely emulate biological conditions. Peptide resonances were assigned, and a range of 






















Figure 2-11: Residue shifts of 
15
N-HSQC spectrum of 
15
N labelled talin F3 with maximum peptide 
concentration. 











Figure 2-12: NMR summary diagrams. Δδ/T< 4ppb/K is the measure of the temperature dependence 
of the amide proton chemical shift. 3JHNHα coupling constant of less than 6Hz (3JHNHα < 6Hz) 
indicates helical structure. Where (▪) represents values which meets the criteria for helical structure, 
(-) for undetermined values due to structure or spectral overlap, (*) for values of 3JHNHα < 6Hz with 
spectral overlap and no symbol is for values determined which are outside the range for helicity. 
Ratios of sequential NN(i,i+1) to αN(i,i+1) NOE intensities of less than one (INN/IαN < 1), are 
indicated. Here, the horizontal line indicates a value of one, with boxes above the line for values >1, 
and boxes below for values <1. Chemical shift indices (CSI) for αΗ resonances are also indicated, 
where boxes above and below the line signify differences from random coil values of > 0.1 or < 0.1, 
respectively.  
H D R K E F A K F E E E R A R A K W
Dd/T <4 ppb/K ◼ ◼ ◼ ◼ ◼ ◼ ◼





H D K K E F D K F E E E R A R A K W
Dd/T <4 ppb/K ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼






H D R K E F A K F E E E R A R A K W
Dd/T <4 ppb/K ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼










H D R K E F D K F E E E R A R A K W
Dd/T <4 ppb/K ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼








H D R K E F A K F E E E R A R A K W
Dd/T <4 ppb/K ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼











C h a p t e r  2   | 56 
 
2.3.5.1 NMR analysis of parent peptide structure 
1H homonuclear NMR spectroscopy was used to gain a better understand of the 
structure of unconstrained peptide β3MP(722-739) to determine how the linker 
location impacted the structures of linked peptides 6 – 9. The β3MP(722-739) displayed 
upfield shifted resonances for 1Hα compared to random coil values30. These shifts 
equated to αH CSI (Chemical Shift Index) values of less than -0.1 for residue 730 to 736 
indicative of α-helical structure 31, 32. Helical structure in this region was further 
supported by 3JHNHα couplings of less than 6Hz for four of the five measurable residue 
resonances (Figure 2-12). This equates to φ angles between -70° and -30°which is typical 
of α-helices33, 34  
The amide protons (NH) temperature coefficients for seven of the β3MP(722-739) 
peptide residues were measured to be -4 ppb/K indicating these residues are involved 
in hydrogen-bonding35, 36. All these residues are located in the C-terminus of the 
peptide, between residues 731-738, consistent with the presence of helical structure in 
this region35, 36. Helical structure is also supported by the presence of αβ(i,i+3) and 
αN(i,i+3) NOE connectivities (4.2.12, Figure 4-13).  
The NMR data described above provides evidence for helical structure, particularly in 
the C-terminal region of β3MP(722-739). However the intensities of NN(i,i+1) NOEs, 
relative to their respective αN(i,i+1) NOEs (INN/IαN) are greater than 1 (Figure 11 and 
4.2.12, Figure 4-13), which is inconsistent with helical structure. Similarly, the large 
intensities of the αN(i,i+1) to αN(i,i) (Iαα/Iαα) NOEs (4.2.12, Figure 4-13) are also 
indicative of more extended structure. This is in closer agreement with the earlier CD 
results for β3MP(722-739) (see section 2.3.3) indicating a greater proportion of 
extended, or random coil, structure present across the length of the peptide37. These 
two opposing sets of evidence are likely due to dynamic reorientation of the peptide in 
solution between extended and helical forms. 
2.3.5.2 NMR analysis of the structure of lactam bridged peptides  
The observed NOEs, coupling constants, temperature dependence of amide chemical 
shifts, and α-proton chemical shifts for lactam bridged peptides 6, 7, 8 and 9 are 
consistent with increased helical structure compared to β3MP(722-739) (Figure 2-12). 
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For each peptide, nucleation extends from the point of linker attachment toward the C-
terminal, with residues in these regions displaying temperature coefficients greater 
than -4ppb/K indicative of a greater number of hydrogen-bonded residues (Figure 2-12). 
The absence of hydrogen bonding between residues on the N-terminal side of the 
linkers of the lactam linker peptides as well as the absence of other indicators suggests 
helicity is not being nucleated towards the N-terminal of the peptide. Unlike the data 
for β3MP(722-739), the lactam linked peptides gave NOE intensity ratios (IαN/INN) and 
(Iαα/Iαα) less than 1 for residues in the helical regions, supporting CSI, 3JHNHα and 
amide temperature coefficients. This suggests more stable helical structures for the 
linked peptides relative to linear peptides. This matches the CD data discussed earlier in 
section 2.3.4.  
NMR structural calculations were performed using the program ARIA38 (Ambiguous 
Restraints for Iterative Assignment) in order to further understand the effect of the 
linker on constraining the structure of each peptide (Figure 2-13). These calculations, 
performed by Dr Kate Wegener, resulted in 20 refined structures for each of the 
peptides studied, β3MP(722-739) and peptides 6 – 9, based on NOE, scalar coupling and 
hydrogen bond restraints (4.2.12, Figure 4-13). The calculated structures for β3MP(722-
739) and peptides 6 – 9 displayed greater helical content (Figure 2-13) than their 
experimental NMR measurements (Figure 2-12). This suggests that the calculated 
structures generate a more static view of a highly dynamic system compared to NMR 
measurements. This is particularly apparent for peptide 8. The calculated peptide 
structures do not depict the level of disorder present in solution, however when coupled 
with the analysis of the raw NMR measurements they produce a useful understanding 


















The calculated structures of β3MP(722-739) depicted in Figure 2-13 suggest that the C-
terminal region is dominated by α-helical structure, while the N-terminal region is 
largely unstructured39. Also depicted in Figure 2-13 are the calculated structures of 
peptides 6 – 9 which reveal unbroken helicity from the linker to the C-terminus. This 
was not supported by the NMR measurements, with chemical shifts for αH CSI values 
downfield of the expected values for the aspartate linker residue indicting helical 
structure. The disruption of helical structure at this point is not supported by 3JHNHα 
coupling constants or IαN/INN values. The evidence above suggests asparagine or 
aspartate residues are not appropriate random coil reference residues, or that the 
proximity of the amide to the αH of this aspartic acid reside could be affecting the αH 
chemical shift. The aspartate linker residues of linked peptides also display large 
negative NH temperature coefficients suggest hydrogen bonding was not present. In 
contrast, the calculated structures consistently exhibited hydrogen bonding at this 
residue. 
Figure 2-13: NMR structure calculations for β3MP(722-739) (purple),  
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The apparent contradiction between structure calculations and NMR measurements 
could be due to the presence of a shortened hydrogen bond for the aspartate linker 
residues, or shielding of the residue by the lactam linker. The length of hydrogen bonds 
involving the NH proton is known to influence the NH temperature coefficients and NH 
secondary shifts35, 36. Shorter hydrogen bonds of less than 2Å are associated with 
downfield shifted NH resonances and temperature coefficients of less than -4ppb/K. The 
calculated structures of lactam bridged peptides 6 – 9 reveal hydrogen bond lengths of 
less than 2Å along the backbone between the residues. However, other hydrogen bonds 
along the backbone had lengths of less than 2Å but did not display NH shifts and 
temperature coefficients outside of the helical range. It is possible that the lactam amide 
group from the lactam bridge linker influences the chemical shifts and temperature 
coefficients associated with the aspartic acid residue. The downfield shifted NH 
resonance of aspartic acid residue suggests a deshielding effect for the linker, however, 
the large negative NH temperature coefficient is more consistent with a shielding effect. 
Based on this contradiction, the length of the hydrogen bond would better explain the 
observed measurements. 
The lysine resides involved in the linker for linked peptides, 6 - 8, display NH 
temperature coefficients greater than -4ppb/K suggest hydrogen bonding along the 
backbone. Peptide 9 displayed a temperature coefficient less than -4ppb/K indicating 
there was no hydrogen bonding along the backbone, attributable to the residue being 
particularly close to the N-terminus. In contradiction, the structure calculations could 
not reliably identify hydrogen bond acceptors, a discrepancy due to the previously 
discussed static structure calculation of a highly dynamic system within solution. 
Decreased disorder in the C-terminal region after the linker was incorporated, as 
suggested by NMR structure calculations, appear to provide an insight into the binding 
affinities of the linked peptides to the talin F3 domain. The linkers of peptides 6 and 8 
are closest to the C-terminus and structure calculations in these cases suggest a more 
disordered N-terminus, with minimal stabilisation outside of the linker region. Peptides 
7 and 9 produced enhanced affinity in comparison to β3MP(722-739), a result 
supported by NMR assertion that the α-helical structure is apparent across the entire 
length of the peptides.  
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Disorder for the key hotspot N-terminal residues, phenylalanine residues F(727) and 
F(730), was significantly reduced for peptide 7 and 9 compared to 6 and 8. Figure 2-14 
shows an overlay of structure calculations of peptide 7 with β3 integrin/PIP kinase 
chimeric peptide bound to talin 1 (Figure 2-14, left) and the crystal structure of 1D and 
talin 2 (Figure 2-14, right). The structure calculations show good agreement in the 
locations of the phenylalanine residues in the crystal structure, however, a similar 
arrangement is seen with peptide 9, and therefore the difference in affinity between 
peptides 7 and 9 remains unclear. Residue K729 in peptide 9 displays 1αH chemical shifts 
similar to those of lysine in a random coil structure, and intensities of the NN(i,i+1) NOE, 
relative to its respective αN(i,i+1) NOEs (INN/IαN), to be greater than 1. These 
measurements suggest residue K729, located between key phenylalanine residues, 
lacks indicators of helicity. Further investigation would be required to verify this 
observation, which, in the future, may be utilised in studies to determine if an optimum 
distance for the placement of a lactam bridge linker from the native structured region 






2.3.6 Protease stability 
Protease require the substrate to adopt an extended -sheet geometry for protease 
binding, and thus they do not hydrolyse residues within a helical structure. The 
hydrolysis of peptides due to protease binding can provide an indication of the stability 
of peptides to cellular conditions, and may suggest the regions of helical structure that 
cannot be accessed the protease. a-Chymotrypsin is known to cleave peptide bonds on 
the C-terminal side of phenylalanine residues, providing two predicted cleavage sites 
for the hydrolysis of integrin peptides, at F(727) and F(730). Liquid chromatography 
Figure 2-14: (B) Left Peptide 7 overlaid with Talin1/b3 peptide (2H7E). Right Peptide 7 (green) 
overlaid with Talin2 (yellow)/b1D peptide (red) (3G9W). 
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coupled with mass spectrometry was used to monitor the chymotrypsin catalysed 
hydrolysis of the parent peptides β3MP(722-739) over time. As expected, treatment of 
the linear peptide β3MP(722-739) with a-chymotrypsin at an enzyme/substrate ratio of 
approximately 1/2500 resulted in rapid hydrolysis of the linear peptide, with a half-life 
of only 14 minutes. The breakdown products were identified by LCMS-ESI, with the 
major ions identified being the products of cleavage adjacent to F(727), however there 
was no evidence of cleavage at F(730). Under the same conditions, just under 90% (as 
measured by ion abundance) of peptide 7 remained after 24 hrs exposure to a-
chymotrypsin. The linker within peptide 7 spans the established cleavage site for a-
chymotrypsin, F(727), with the alternative cleavage site of F(730) immediately adjacent 
to the linker, see Figure 2-12. The increase in protease stability observed for peptide 7 
relative to β3MP(722-739) may be due to the linker blocking entry of the peptide to the 
active site, as well as increased helical structure and a consequential decrease in -sheet 
geometry required for hydrolysis.  
Peptide 6 was similarly treated with chymotrypsin to determine the stability of a linked 
peptide when the cleavage site was not between the linked residues. While the lactam 
bridge linker does not span or involve a residue close to F(727) the half-life for peptide 
6 was significantly extended to 43 minutes with comparison to the linear peptide, 
β3MP(722-739) with a half-life of 14 minutes. These results suggest that the secondary 
structure induced by the linker hinders the proteases ability to bind the peptides in the 
extended β-strand structure.  
C h a p t e r  2   | 62 
 
  
Figure 2-15 Time course of β3 peptide cleavage by chymotrypsin. β3MP(722-739) (●), peptide 
7 (◼) and peptide 6 (▲). Curves indicate the fit to non-linear regression exponential one phase 
decay.  
 
These results confirm that a suitably placed lactam bridged linker increases resistance 
to proteolysis. The preferred site of cleavage for a-chymotrypsin in the linear peptide, 
β3MP(722-739), was F(727) suggesting that this cleavage site was more accessible to a-
chymotrypsin than F(730) which is closer to the C-terminal end. This may be due to 
native helical structure present in this region of the linear peptide, β3MP(722-739), as 
revealed by the NMR studies discussed in section 2.3.5.  
 
2.3.7 Conclusions 
The studies undertaken in this chapter reveal that linker location has significant impact 
on both peptide helicity and on determining the binding affinity peptides and the talin 
F3 domain. While all peptides with linkers incorporated resulted in increased structural 
content when compared to the linear peptide β3MP(722-739) , this was not the case for 
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binding affinity. Stabilisation of helical structure did not necessarily produce enhanced 
affinity, even when bridged residues are on the opposite face to the binding residues. 
Detailed structural analysis using NMR spectroscopy of both the parent peptide 
(β3MP(722-739)) and linked peptides revealed nucleation occurred only in a single 
direction, on the C-terminal side of the linker, appearing to extend toward the native 
tendency for helical structure present at the C-terminal end of β3 integrin peptide. 
These findings demonstrate the importance of identifying the structural characteristics 
of partially structured patent peptides, as a means to provide insight into the optimum 
location for incorporation of a helical inducing linker. Helical structure at the C-terminal 
of the linear peptide (β3MP(722-739)) is supported by the proteolysis results, with 
residue F(730) protected from cleavage. The difference in the structure of peptides 7 
and 9 are subtler, and yet results in a clear difference in affinity to F3 talin. Further 
investigation into the structural complexities of these peptides may produce finding that 
will assist with the determination of the optimum position for side chain linkers in the 
future. The evidence gathered here suggests that a constraint should be located in a 
region of low structural propensity avoiding key residues, which can be identified with 
Robetta online alanine scan server. In this case, a constraint on the N-terminal side of 
these residues resulted in helix stabilisation. Future work is required to produce 
optimised inhibitors selective for the integrin binding site of talin, with these peptides 
providing important leads in the development of a new class of anti-thrombotic 
therapeutic with a novel mechanism of action.   
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3.1 Comparison of α-Helical Side Chain Linkers 
Comparative studies on peptides containing different side chain linkers provide an 
opportunity to streamline the design of helical peptides for biological applications. To 
date, studies have compared different types of functional groups joining peptide side 
chains based on the resulting peptides helicity. A study by Frankiewicz et al1 compared 
four peptides with linkers connecting the i and i+4 residues of sequences derived from 
vasoactive intestinal peptide (VIP). These peptides were linked by amide bond 
formation (lactam KE linker, A(ii)), Huisgen azide-alkyne cycloaddition (triazole linker, B) 
and olefin ring closing metathesis (saturated and unsaturated diether linkers, C and D 
respectively) (Figure 3-1). An analysis of the circular dichroism (CD) of each revealed 
that the triazole linked peptide had the greatest α-helical content of the four peptides. 
 
Figure 3-1: Side chain-side chain linkers, A (i) lactam (KD) (ii) lactam (KE), B triazole, C 
unsaturated diether, D saturated diether, E all-hydrocarbon, F alkyl thioether, G 
perfluorobenzyl thioether (PF benzyl) and H m-xylene thioether, which link i and i+4 residue 
side chains.  
 
A B C D 
E F G H 
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Studies of individual linker types which compared length and positioning2-7 indicate that 
the linkers incorporated by Frankiewicz et al1 were not optimal for generating peptides 
the greatest α-helical content. Linker types later investigated by de Araujo et.al8 were 
selected from these optimised linkers. Model peptides were synthesised with lactam 
(KD) (A(i)), triazole (B), all-hydrocarbon (E), alkyl thioether (F), perfluorobenzyl thioether 
(PF benzyl, G) and m-xylene thioether (H) linkers, see Figure 3-1. The linkers joined the 
i and i+4 residues in pentapeptides with alanine residues between linking residues, and 
in 18-residue peptides. The 18-residue sequence contained predominantly alanine, with 
addition of arginine residues to ensure the peptides would be soluble in water. Analysis 
of CD and NMR spectra of these peptides showed that the lactam-linked pentapeptide 
(A(i)) had the greatest α-helical content, with the all-hydrocarbon (C) and triazole (B) 
linked peptides displaying slightly lower helicity. The other peptides showed 
comparatively lower helical content. The longer 18 residue peptides containing lactam 
(A(i)), all-hydrocarbon (C) and triazole (B) linkers gave similar results, with the percent 
helicity for the lactam linked peptide greater than that for peptides with the triazole 
and all-hydrocarbon linkers. However, it is unknown if these findings are transferable 
to other peptide sequences. Lactam, triazole and all-hydrocarbon linked peptides based 
on the β3 integrin sequence were therefore prepared in order to see if the lactam bridge 
also displayed the highest helical content in these cases. 
 
3.2 Cellular Uptake  
Currently available therapeutic peptides predominantly target extracellular proteins, 
rather than intracellular proteins. However, Verdine and co-workers9 have shown that, 
for some peptide sequences, the introduction of an all-hydrocarbon linker causes the 
peptide to be taken up into cells. Current data suggests that increasing peptide positive 
charge also enhances cellular uptake, with a lesser role apparent for other peptide 
attributes, such as helicity and specific residues10. Investigations of all-hydrocarbon 
linked peptides conclude that cellular uptake is facilitated by the hydrophobicity of the 
component linker10. Cellular uptake of these peptides likely occurs through a clathrin- 
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and caveolin-independent endocytosis pathway that involves, in part, sulfated cell 
surface proteoglycan11.  
Peptides containing a PF benzyl linker are reported to show comparable cellular uptake 
properties to all-hydrocarbon linked peptides12 13. Results of fluorescence-activated cell 
sorting (FACS) analysis and confocal images of HEK293T cells treated with fluorescently-
tagged macrocyclic peptides suggest that peptides containing all-hydrocarbon and PF 
benzyl linkers display similar and favourable cellular uptake properties12. However, 
other peptide linkers are yet to be included in such comparative studies, studies that 
are required to fully exploit linked-peptide therapeutic potential. The cellular uptake of 
peptides that incorporated lactam, triazole and all-hydrocarbon linkers, based on the 
β3 integrin sequence, were therefore investigated and compared in this thesis. 
 
3.3 Design of Peptides for Comparative Studies of Helicity and Cellular Uptake 
The ability of different linker types to induce helicity and influence cellular uptake has 
rarely been compared using a single peptide sequence, due in part to difficulties in 
optimising cyclisation protocols for each linking strategy14. The report by de Araujo et 
al8, discussed in section 3.1, compared the helical content of model peptides containing 
common side chain linkers. This study found that lactam (KD), all-hydrocarbon and 
triazole linkers (Figure 1) produced highly helical peptides, with the lactam linker 
producing the greatest α-helical content8. However, it is not known if the lactam linker 
confers ‘optimal’ helicity in other sequences, particularly biologically relevant 
sequences. In addition, the effect of these linkers on cellular uptake was not 
investigated. In this chapter, four linkers were selected for comparison with peptides 
incorporating these linkers investigated for their helical content and cellular uptake. The 
selected linkers were either chosen for their ability to confer high helical content or 
allow for cellular uptake. Lactam, triazole and all-hydrocarbon linkers were selected 
based on the high helical content displayed for linked peptides in the study by de Araujo 
et al8. All-hydrocarbon and PF benzyl linkers were selected as peptides incorporating 
these linkers showed positive cellular uptake properties in previous studies12 13. The 
sequence selected for this study was the membrane proximal region of the β3 integrin 
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tail, as it may be used to target an intercellular protein, talin, and is therefore 
biologically relevant. This sequence is also very different to previously studied 
sequences as it contains few alanine residues. 
The sequence selected from the β3 integrin tail contained 18 residues spanning from 
H722 to W739. The native sequence is shown for the linear peptide: β3MP(722-739) 
(Table 3-1, Entry 1). Linkers were incorporated between the side-chains of residues 725 
and 729, as this was identified to be the optimal lactam linkage site based on helicity 
and affinity for the talin F3 domain (see Chapter 2). The target peptides for linker 
analysis were thus: linear peptide, β3MP(722-739), lactam linked peptide, 7, triazole 
linked peptide 10, and all-hydrocarbon linked peptide, 11 (Table 3-1, Entries 1-4). 
 
 
a 6-azido L norleucine, b propargylglycine,  
c (S)-2-(((9H–fluoren-9-yl)methoxy)carbonylamino)-2-methyl-hept-6-enoic acid 
 
The effect of linker type on peptide cellular uptake was investigated using fluorescent 
tagged (carboxyfluorescein) linked peptides. Tagged peptides included: linear peptide, 
Fβ3MP(722-739), lactam linked peptide, F7, triazole linked peptide, F10, and all-
hydrocarbon linked peptide, F11, (Table 3-1, entries 5-8).  
Peptide Linker Z X1 X2 
β3MP(722-739) None H Lys Lys 
7 Lactam H Lys Asp 
10 Triazole H Nle (εN3)a Prab 
11 All-hydrocarbon H S(5)c S(5) c 
Fβ3MP(722-739) None β Ala- CF Lys Lys 
F7 Lactam β Ala- CF  Lys Asp 
F10 Triazole β Ala- CF Nle (εN3)a Pra 
F11 All-hydrocarbon β Ala- CF S(5) c S(5) c 
Table 3-1: Peptides used in the current study, derived from the β3 integrin cytoplasmic tail. 
Residues 725 and 729 represented by X1 and X2 respectively (orange). The presence or absence 
of an N-terminal fluorescent label is indicated by Z, where Z is carboxyfluorescein (CF).  
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Comparison between the cellular uptake of these peptides and their helical structure 
will help determine which of helical structure or linker chemistry has the greater 
influence on cellular uptake. This detailed analysis of peptide helicity and cellular uptake 
is expected to streamline the choice of strategies for future development of helical 
peptide therapeutics. 
3.3.1 Synthesis of Triazole, All-Hydrocarbon and Lactam Linked Peptides, 7, 10 and 11 
Peptides containing lactam, triazole and all-hydrocarbon linkers, 7, 10 and 11 
respectively in Table 3-1 (entries 2-4), with linkers shown in Figure 3-2B, were 
synthesised to answer the first of the questions posed in section 3.3: “Which of the 
linkers would result in the greatest helical structure in a biologically relevant 
sequence?” 
Peptides β3MP(722-739), 7, 10 and 11 (see Table 3-1 for the sequences) were 
synthesised using Fmoc solid phase peptide synthesis protocols15 detailed in the 
experimental section (4.3). The synthesis of β3MP(722-739) and cyclisation of peptide 
7 is described in 2.3. Cyclisation of peptide 10 was carried out in solution after cleavage 
from resin. The formation of the triazole linker in peptide 10 was achieved using Huisgen 
cycloaddition of the azide and alkyne groups on the side chains of residues Nle(εN3) and 
Pra (Figure 3-2A) with copper (II) sulfate pentahydrate as the catalyst. Peptide 11 was 
cyclised via ring closing metathesis (RCM). Fmoc protected, resin bound peptide 
(D(723)-W(739)) was treated with Grubbs second generation catalyst, lithium chloride, 
and heated using microwave irradiation16. Cyclisation was completed after two cycles 
of microwave irradiation. Deprotection of the Nα-Fmoc group from the resin-bound 
cyclic peptide and cleavage from the resin gave peptide 11. The highest yield of peptide 
11 was obtained when the RCM was performed on a 0.05 mmol scale, with lithium 
chloride added to the reaction mixture. Lithium chloride was used to disrupt 
unfavourable hydrogen bonding interactions that would be expected to hinder the 
formation of the complex between alkene groups of (S)-2-(((9H–fluoren-9-
yl)methoxy)carbonylamino)-2-methyl-hept-6-enoic acid (S5) residues (Figure 3-2A) and 
the ruthenium catalyst17, 18, which resulted in lower levels of cyclic product (Table 3-1, 
entry 4). Peptides 7, 10 and 11 were characterised using mass spectrometry and their 
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purity determined to be greater than 95% using analytical HPLC (see 4.2.9and 4.3 for 
experimental details).  
 
 
Figure 3-2 (A) Amino acids, Lys and Asp, Nle(εN3) and Pra, S(5) and S(5), incorporated at i and 
i+4th positions to allow for cyclisation to produce linked peptides 7, 10 and 11 respectively. (B) 
The linked section of the peptides produced after cyclisation of i and i+4th residue side chains 
for peptides 7, 10 and 11, where R1=Glu, R2=Phe and R3=Ala.  
 
3.3.2 Structural Comparison of Triazole, All-Hydrocarbon and Lactam Linked Peptides 
7, 10 and 11. 
Circular dichroism spectra of triazole (7), all-hydrocarbon (10), and lactam (11) linked 
peptides were recorded in phosphate buffer (Figure 3-3) to determine which constraint 
induced the most helical structure. The experimental parameters used in CD 
measurements were obtained from previous work on the characterisation of short 
helical peptides reported by Shepherd et al.19. The maximum molar ellipticity was 
determined using the equation: [θ]max = (−44 000 + 250T)(1 − k/n), where temperature 
(T) was 298K, number of non-bonded carbonyls (k) was 4, and number of residues (n) 
A 
B 
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was 18. The ratio of calculated molar ellipticity to measured maximum molar ellipticity 
(λ = 222 nm) was used to determine percent helicity (detail provided in 4.1.2.2).  
 
All linked peptides 7, 10 and 11 displayed markedly greater percent α-helicity (58-62%) 
than the linear peptide, β3MP(722-739) (23%), indicating all linkers were able to 
stabilise helical structure as expected. α-Helical content of linked peptides increased in 
the order: lactam-linked 7 (57%) < all-hydrocarbon linked 11 (60%) < triazole linked 10 
(62%) (Figure 3-3, left, Table 3-2), indicating the triazole linker induced the most helicity 






Figure 3-3: CD spectra for β3MP(722-739) (red), lactam linked 7 (green), triazole linked 10 
(blue) and all-hydrocarbon linked 11 (black) illustrating linker effect on helical content (left: 
10 mM phosphate buffer, pH 6.5, 298K, right: 10 mM phosphate buffer, 10% TFE, pH 6.5, 
298K). 
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Table 3-2: Molar ellipticity [θ] (deg cm2 dmol-1 residue-1) at 222 nm, percentage helicity and 
ratios of ellipticity at 222 nm/208 nm for β3MP(722-739) peptides, 7, 10 and 11 determined 
from CD data acquired in 10 mM phosphate buffer (pH 6.5, 25oC). 
a Molar ellipticity [θ] (deg cm2 dmol-1 residue-1) at 222 nm, acquired from CD data 
b percent helicity 
c ratios of ellipticity at 222 nm/208 nm  
 
The ratio of molar ellipticity at 222 nm to that at 208 nm ([θ]222/[θ]208), is often used as 
a measure of helix ideality, with a value of ~1 indicating optimal α-helical structure20. 
The deeper minima at 208 nm compared to 222 nm, seen in the CD spectrum of peptide 
7 in particular, suggests the peptides contain a mixture of α-helical structure and 310 
helical structure or unstructured regions. The greatest ratio of [θ]222/[θ]208 was 0.95 for 
the triazole-linked peptide 10, making it the peptide closest to ideal α-helical structure. 
Next was, the all-hydrocarbon-linked peptide 11 (0.88), followed by the lactam peptide 
7 (0.76) (Table 3) i.e. the same order observed for percent helicity.  
To determine if the peptides were demonstrating their maximal helicity, 10% TFE was 
added to the solution as it is a known helix inducing solvent21. All peptides showed an 
increased helicity with addition of 10% TFE (Figure 3-3, right, Table 4-1). This suggests 
that helical content has not been maximised by any of these constraints, likely due to 
their long length (18 residues), and suggests that additional constraints along the length 
of the peptides may lead to a further increases in helical structure for all linker types.  
The results of this study suggest peptide 10, containing the triazole linker, displayed the 
greatest helical content, followed by 11 (all-hydrocarbon linker), and then 7 (lactam 
linker). In contrast, de Araujo et al.8 study suggest the lactam linked peptides display 
the greatest helicity when compared to all-hydrocarbon and triazole linked peptide, for 
model pentapeptides and longer 18-mer peptides. The discrepancy between the 18-
Peptide [θ]222a Helicityb [θ]222/[θ]208c 
β3MP(722-739) -8106.49 23% 0.55 
7 -13121.9 57% 0.76 
10 -18123.6 62% 0.95 
11 -17622.2 60% 0.88 
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mer peptide synthesise by de Araujo et al.8  and the 18 residue peptides 7, 10, 11 is 
likely due to the differences in peptide sequence; the present study uses a biologically 
relevant sequence, consisting of charged and polar residue, while the de Araujo et al.8 
peptides were mostly comprised of alanine residues. This suggests that the specific 
peptide sequence plays an important role in determining the ‘optimal’ linker to nucleate 
helicity. Therefore, it cannot yet be generalised that either lactam or triazole linkers will 
nescessarily produce peptides with greatest helical content. More general conclusions 
require further study into sequence effects and linker types on the helical content of 
peptides. The integrin sequence may in fact favour a particular form of helical structure, 
which varies from the ideal α-helix, specific for its native protein-protein interaction 
with talin.  
All three linkers, lactam, all-hydrocarbon and triazole, produce peptides with 
consistently high helicity in both this study and the study performed by de Araujo et 
al.8. Producing a peptide with the highest helical content possible may not be of utmost 
importance in all studies using helical peptides. Other favourable characteristics of the 
linked peptide may be required depending on their application. One such desirable 
quality is cellular uptake, which was therefore investigated in the following section, 
using fluorescently tagged peptides.  
 
3.3.3 Synthesis of Fluorescent Peptides F7, F10 and F11 with Triazole, All-Hydrocarbon 
and Lactam Linkers  
The 18-residue peptides derived from the integrin tail, containing lactam, triazole and 
all-hydrocarbon linkers, were tagged with carboxyfluorescein to produce Fβ3MP(722-
739), F7, F10 and F11 (Table 3-1, entries 5-8, general structure shown in Figure 3-4), in 
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Figure 3-4: General structure for carboxyfluorescein tagged peptides, Fβ3MP(722-739) F7, F10 
and F11. Residues X1  and X2 identity as displayed in Table 3-1.  
The fluorescently tagged peptides Fβ3MP(722-739) F7, F10 and F11 (Table 3-1, entries 
5-8 for the sequences) were synthesised using Fmoc solid phase peptide synthesis 
protocols15 incorporating carboxyfluorescein (Figure 3-4) as detailed in the 
experimental section (4.3). Linkers were produced via cyclisation as previously 
described for peptides 7, 10 and 11 to give peptide F7, F10 and F11 respectively. 
Additionally, a positive control, CF-NYAD-1, was synthesised for the comparison of 
confocal microscope images in cellular uptake studies. This peptide was based on NYAD-
1, a peptide previously used to compare cellular uptake of linked peptides by Spokoyny 
12. The addition of the carboxyfluorescein group was achieved by the coupling of Fmoc-
β-alanine-OH followed by carboxyfluorescein to the N-terminus of the peptide 
synthesised as described by Zhang et.al13. These peptides were characterised by mass 
spectrometry and their purity confirmed to be greater than 95% by HPLC.  
3.3.4 Cellular Uptake of Triazole, All-Hydrocarbon and Lactam Linked Peptides 
To determine cellular uptake, tagged peptides Fβ3MP(722-739), F7, F10 and F11 as well 
as controls CF and CF-NYAD-1 (5 μM) were separately added to NIH 3T3 mouse 
embryonic fibroblast cells. The cells were incubated with peptides for 3 hrs, after which 
the cells were washed to remove peptide remaining in the media. Samples were 
trypsinised to remove any peptide on the cell surface. These cells were then fixed to 
glass slides and imaged using confocal microscopy. Confocal images of peptides F10 and 
F11 displayed clear, green punctate fluorescence, consistent with the peptides being 
localised in endosomes within cells (Figure 3-5). Lower levels of green punctate 
fluorescence are seen in images of Fβ3MP(722-739) and F7, suggest low levels of 
cellular uptake for both these peptides. Negative control cells, treated with 
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carboxyfluorescein (CF) alone, displayed low levels of background fluorescence. Positive 
control cells, treated with CF-NYAD-1, displayed punctate fluorescence similar to cells 
treated with F10 and F11. However, cellular uptake was significantly greater for CF-
NYAD-1, which displayed higher intensity fluorescence in confocal images.  
 
 
To verify cellular uptake of the peptides was not limited to one cell line, cellular uptake 
was also investigated in human HeLa cells, an immortal cell line derived from human 
cervical cancer cells. Cells were treated with peptides F10, F11, CF, and CF-NYAD-1, 
using the same protocols as previously described for the cellular uptake studies using 
NIH 3T3 cells. Confocal images of treated HeLa cells showed similar results to those of 
mouse NIH 3T3 cells, however HeLa cell images displayed higher background 
fluorescence, as seen in images of the negative control cells treated with CF (Figure 3-6). 
Fluorescence in cells treated with peptides F10 and F11 was clearly above background, 
and was observed as green punctate fluorescence, once again likely due to the peptide 
being localised in cellular endosomes.  
Figure 3-5: Fluorescent confocal microscopy images of mouse NIH3T3 cells treated 
with CF (carboxyfluorescein, green fluorescence), CF-NYAD-1, FβMP(722-739), F7, 
F10 and F11. Cells were stained with DAPI nuclear stain (blue fluorescence). Scale 
bars represent 10μm. 




The mean cellular fluorescence was used to quantify the extent of cellular uptake for 
each peptide (Figure 3-7) using fluorescence activated cell sorting (FACS), a specialised 
type of flow cytometry. Tagged peptides Fβ3MP(722-739), F7, F10 and F11 (5 μM) were 
each added to NIH 3T3 mouse embryonic fibroblast cells. The cells were incubated with 
the peptides for 3 hrs, after which the cells were washed to remove peptide remaining 
in the media. Samples were trypsinised as described above to remove any peptide on 
the cell surface. Peptide F11 with the all-hydrocarbon linker was found to have the 
greatest mean fluorescence indicating highest cellular uptake. F10 displayed lower 
cellular uptake than F11, but greater cellular uptake than F7, suggesting that linker type 





Figure 3-6: Fluorescent confocal microscopy images 
of HeLa cells treated with: CF (carboxyfluorescein), 
CF-NYAD-1, F10 and F11. Scale bars represent 10μm. 












The basis of the differences between the cellular uptake of F11, F10 and F7 is likely 
related to the linker properties and peptide helicity. In terms of helicity dictating the 
levels of cellular uptake, the triazole linked peptide (F10) should display the greatest 
cellular uptake followed by the all-hydrocarbon linked peptide (F11) and then the 
lactam linked peptide (F7) according to helical content as determined by CD 
spectroscopy of the untagged peptides. The lactam linked peptide F7 does have the 
lowest cellular uptake of the three linked peptides, consistent with this peptide also 
having the lowest helical content, however F11 displays greater cellular uptake than 
F10, with 10 displaying greater helical content than 11. This suggests that the extent of 
helicity alone does not explain the observed cellular uptake trend. It is possible the 
polarity of the linker plays a role in dictating the levels of cellular uptake22, with the all-
hydrocarbon linker displaying the lowest levels of polarity, compared to the triazole and 
amide linkers. However the triazole is likely less hydrophobic than the amide23, with the 
amide displaying a dipole moment of 3.5 D24 while the triazole displays a dipole moment 
of 5 D25. Alone hydrophobicity of the linker and peptide helicity cannot explain the 
pattern of cellular uptake, with F11 showing the greatest cellular uptake followed by 
Figure 3-7: (Left) Representative graph of FACS analysis of NIH 3T3 cell treated with Fβ3MP(722-
739) (red), F7 (green), F10 (blue), F11 (black) (5μM), indicating the number of cells (cell count) 
with each level of fluorescence intensity, and (Right) Histogram displaying mean fluorescence 
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F10 and then F7 (Figure 4), suggesting the linker polarity and peptide helicity both play 
a role in cellular uptake. 
Previous studies suggest a positive correlation between peptide helicity and cellular 
uptake26. Interestingly, Fβ3MP(722-739) displayed greater cellular uptake than F7. This 
is unexpected as untagged peptide 7 with the lactam linker displayed the greater 
percentage helicity (57%) than the linear peptide β3MP(722-739) (23%), as identified in 
CD analysis and confirmed by NMR studies (2.3.5). The cause of lower levels of cellular 
uptake of F7 in comparison to Fβ3MP(722-739) may be due to the difference in overall 
peptide charge. The original linear peptide sequence (overall charge +2) contains two 
free positively charged lysine residues, which are modified to neutral linkers in peptides 
F7, F10 and F11. Increasing the number of positively charged residues in a peptide has 
previously been associated with greater cellular uptake of the peptides11. This result 
suggests the presence of the positively charged lysine residues in the native sequence, 
Fβ3MP(722-739) , had a greater impact on cellular uptake than the incorporation of a 
lactam bridge, despite F7 having the greater helical content. As such the effect of charge 
of the peptide on cellular uptake was investigated in the following section. 
3.3.5 Investigation into the Effect of Peptide Charge on Cellular Uptake of the β3 
Integrin Tail 
A panel of short 14-mer peptides derived from the β3 integrin sequence H(722)-A(735) 
(2.3.2) were synthesised with hydrocarbon linkers incorporated to investigate the effect 
of peptide charge on cellular uptake. Overall peptide charge was varied by altering the 
peptide sequence based on a study by Bernal et al.27. Bernal et al.27 reported a short 
peptide with an all-hydrocarbon linker which did not display cellular uptake, which was 
attributed to the negative charge of the peptide. The authors synthesised a panel of 
peptides in which negatively charged residues were substituted with either neutral or 
positively charged side chains. Peptides with an overall neutral or positive charge 
displayed cellular uptake, while the original sequence (overall negative charge) did 
not27.  
The 14-mer β3 integrin sequence H(722)-A(735) was used as the basis for fluorescently 
tagged peptides F13, F14, F15 and F16 (Table 3-3). Peptide F13 (Table 3-3, entry 1) has 
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an overall charge of -2 and consisted of the native residues, apart from residues at 
positions 725 and 729 (assigned the letter X in Table 3-3) that were modified to 
incorporate the hydrocarbon linker. Negatively charged residues were substituted with 
either neutral or positively charged residues for peptides F14, F15 and F16, except for 
residues E726 and E733 as they are likely involved in charge related interactions within 
the peptide, or with talin (2.3). Peptide F14 was designed with all non-critical negatively 
charged residues replaced with either glutamine or asparagine, resulting in a peptide 
with +1 charge. These residues in peptide F15, were substituted with arginine to further 
increase the overall charge to +4. To assess whether changes in peptide uptake were 
due to arginine residues being located at specific sites, F16 was synthesised for 
comparison, where the arginine residues were added to the N-terminus and non-critical 
negatively charged residues in the sequence were replaced with either glutamine or 
asparagine, giving a peptide with the same +4 charge.  
Peptides F13, F14, F15 and F16 were synthesised manually from A(735) to H(722) 
incorporating non-natural amino acid S5 (Figure 3-2) in the i and i+4th positions, shown 
as residue ‘X’ in Table 3-3. Resin bound Fmoc protected peptides were cyclised by ring 
closing metathesis, as described for peptide 10. After cyclisation, β-alanine and 
carboxyfluorescein were coupled to the resin bound peptide. Peptides were then 
cleaved from the resin to produce F13-16., which were characterised by mass 
spectrometry and analytical HPLC. 
Table 3-3: Sequence and charge for peptides 
F13, F14, F15 and F16. All-hydrocarbon linkers 
are incorporated, C-terminal amidated and N-







Peptide Sequence Charge 
F13 HDRXEFAXFEEERA -2 
F14 HNRXEFAXFQQERA +1 
F15 HRRXEFAXFRRERA +4 
F16 RRRHNRXEFAXFQQERA +4 
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NIH 3T3 cells were treated with fluorescein labelled peptides, F13, F14, F15 and F16, 
and incubated for 3 hrs before cells were rinsed and trypsinised to remove peptides 
bound to the cell surface. Cells were then analysed using FACS and results for mean 
fluorescence intensity were used to infer peptide levels within cells (Figure 3-8). Cells 
treated with negatively charged peptide F13 (-2) and positively charged peptide F14 (+1) 
displayed no significant difference in mean fluorescence intensities. This suggests that 
negative charge was not the major contributing factor to low cellular uptake of F13. 
Cells treated with F16 had the highest mean fluorescence intensity of the 4 samples. 
Cells treated with F15 displayed greater cellular uptake than either F14 or F13, however 
mean fluorescence intensity was much less than that of F16. This result was unexpected 
as F15 and F16 had the same overall charge. These results suggest that location of 
positively charged residues affects cellular uptake of peptides, and that the positive 
charge grouped at the N-terminal was more effective for increasing cellular uptake of a 





































Figure 3-8: (Left) Representative graph of FACS analysis of NIH 3T3 cell treated with 
carboxyfluorescein (CF, yellow) F13 (red), F14 (green), F15 (blue) and F16 (black) (5μM), and 
(Right) Histogram displaying mean fluorescence from three experiments displaying errors bars 
indicating standard deviation. Comparison between all measurements using a two-tailed t-test 
indicated a p>0.05, except for F13 with F14.  
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Confocal images taken of NIH 3T3 cells treated with F13, F14 and F16 displayed green 
puncta fluorescence within cells, confirming peptides were entering the cells (Figure 7). 
The intensity of fluorescence in confocal images were consistent with the data from 
FACS analysis.  
 
 
3.3.6 Design and Synthesis of Perfluorobenzyl Thioether (PF benzyl) Linked Peptides 
The final study aimed to determine the effect of PF benzyl linkers on integrin peptide 
helical content and cellular uptake, as PF benzyl linked peptides were identified as 
peptides displayed high cellular uptake in a report by Spokoyny et al. 12. In the work by 
Spokoyny et al. 12 the PF benzyl linker was found to induce helical structure, and 
produced a peptide that displayed cellular uptake comparable to that of the equivalent 
all-hydrocarbon linked peptide. However, the subsequent study by de Araujo et al.8 
found a pentapeptide peptide containing the PF benzyl linker was not highly helical, 
when compared to lactam, all-hydrocarbon and triazole linked peptides.  
PF benzyl linked peptides 12 and F12 (Figure 3-10) were synthesised via Fmoc solid 
phase peptide synthesis using an automated peptide synthesiser and characterised by 
mass spectrometry and HPLC. Cysteine residues incorporated at positions 725 and 729 
(i to i+4) were linked to produce the PF benzyl linkers in solution on treatment with 
hexafluorobenzene. Nucleophilic aromatic substitution at positions 1 and 4 of 
hexafluorobenzene was achieved via reaction with the cysteine residue sulfhydryl 
groups (Figure 3-10).  
Figure 3-9: Representative fluorescent confocal microscopy images of mouse NIH 
3T3 cells treated with F13, F14 and F16. Scale bars represent 10μm. 
F13 F14 F16 




The cyclisation reactions were low yielding (less than 2%) due to precipitation of the 
peptides on addition of tris base. The low solubility of the peptides in DMF could be 
overcome by addition of water, however this also stopped the reaction with 
hexafluorobenzene. Additionally, peptides were purified before and after cyclisation by 
semi-prep HPLC which likely further reduced peptide yields. In an attempt to improve 
the amount of peptide recovered after cyclisation, on resin cyclisation was attempted 
using a previously described protocol involving selective removal of cysteine protecting 
groups (Mmt) and  cyclisation with 1,4-dibromo-2,3,5,6-tetrafluorobenzene and DIPEA 
in DMF8. However, after the on-resin cyclisation, masses for the expected cyclic 
products were not identified in the LCMS spectrum, indicating this cyclisation protocol 
was not effective for PF benzyl linked peptides.  
 
3.3.7 Structural Analysis of Perfluorobenzyl Thioether Linked Peptide 
The CD spectrum of peptide 12 (Figure 3-11, left) displays features characteristic of 
helical structure. A maximum around 190 nm is a clear indicator of helical structure. The 
minimum at 205 nm, is slightly shifted from the expected 208 nm, providing an 
indication of low levels of helical structure. The shallow minimum observed at 222 nm 
would normally suggest low helical content, however, Spokoyny et al. 12 identified an 
absorbance maximum around 222 nm in the CD spectrum12 for peptides containing PF 
benzyl linkers due to the presence of the C6F4 group. Therefore, absorbance of the linker 
 
 
12: X=H  F12: X=βAla-CF 
Figure 3-10: PF benzyl linker incorporated in Peptides 12 where X=H and F12 where X= 
βAla-CF. The PF benzyl linker is highlighted in orange.  
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will mask any minimum due to helicity, making alternative methods for determining 
helicity necessary. 
 
The original report by Spokoyny et.al made a semi-quantitative estimation of percent 
helicity for peptides containing the PF benzyl linkers12 by correcting for the ellipticity of 
the perfluorobenzyl group at 222 nm. This estimation involves subtracting the mean 
residue absorbance of the ‘control’ CD spectrum (perfluorobenzyl group connected to 
two fully protected cysteine amino acids) from the measurement obtained for the full 
PF benzyl cyclised peptide. This method was applied to the mean residue ellipticity at 
222 nm for peptide 12, to obtain a ‘corrected’ value, which was used to determine the 
percent helicity. α-Helical content of 12 was estimated to be 74% using this method.  
de Araujo et al8 also investigated the effect of a PF benzyl linker in a short peptide using 
characteristics of the CD spectrum to determine relative helicity. In their study, CD 
spectra of helical peptides were compared to the spectrum of the PF benzyl linked 
peptides. The lack of maxima at 190 nm in particular suggests little α-helical structure 
for the short PF benzyl linked pentapeptide8. In the present study, a similar analysis of 
helicity was performed by comparing the CD spectrum of 12 with the linear peptide 
β3MP(722-739) (Figure 3-11, right). The CD spectrum of 12 displays a lower maximum 
at 190 nm than that of β3MP(722-739) suggesting lower levels of helical structure. 
Peptide 12 displays a minimum at 205 nm, while β3MP(722-739) displays a minimum at 
Figure 3-11: CD spectra of (left) 12 and (right) 12 overlayed with β3MP(722-739), illustrating 
the effect of the linker on helical content. (10 mM phosphate buffer, pH 6.5, 298K) 
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204 nm, this slight shift toward 208 nm, indicative if helical structure, and suggests the 
PF benzyl linker increases helical content of the peptide. Linked peptides 7, 10 and 11 
(section 3.3.2), of the same sequence, display minima at 208 nm, suggesting the PF 
benzyl linked peptide has lower helical content. The similarities in the CD spectra of 
β3MP(722-739) and peptide 12 suggests that the structures of the two peptides are 
similar. As β3MP(722-739) had a percent helicity of 25%, peptide 12 is likely to also have 
approximately 25% helicity.  
Two extremely different estimates of helical content were determined for peptide 12, 
74% and 25%, using methods previously applied to PF benzyl linked peptides. These 
results suggest that Spokoyny et.al12 method of subtracting the mean molar ellipticity 
of PF benzyl linker at 222 nm provides a higher estimate of helicity than de Araujo et 
al8. This may give an over estimate of helical structure given the lack of other features 
expected in the spectrum. However, using the CD spectra characteristics to compare 
peptide helicities, similar to the method presented by de Araujo et al8, may 
underestimate helical content due to the absorbance of the perfluorobenzyl group. 
These results suggest CD spectroscopy is not the best method for characterisation of PF 
benzyl linked peptide structure. Therefore, alternative methods, such as NMR 
spectroscopy, may give a more accurate determination of helicity for these peptides. 
3.3.8 Cellular Uptake of Perfluorobenzyl Thioether Linked Peptide 
Peptide F12 was used to investigate cellular uptake of PF benzyl linked peptides in two 
cell lines. Fluorescein tagged peptide F12, positive control CF-NYAD-1, and negative 
control CF were added to mouse NIH T3T cells and human HEK 293 cells. Cells were 
incubated for 3 hrs, before being washed and trypsinised. Green punctate fluorescence 
was observed within the cytoplasm indicating significant uptake of F12, similar to the 
positive control CF-NYAD-1 (Figure 3-12). These results are consistent with those 
reported by Spokoyny et al which show the PF linked peptides have significant cellular 
uptake.12 
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FACS analysis of cells treated with F12 was not attempted due to the low yields acquired 
from cyclisation reactions. Further work is required to optimise cyclisation conditions, 
such that enough peptide can be obtained to quantify the cellular uptake and directly 









Figure 3-12: Confocal microscopy images of NIH 3T3 mouse cells (top) and 
human HEK 293 cells (bottom) treated with CF, CF-NYAD-1 and F12. Scale bars 
represent 10μm. 




Four different linker types (lactam, triazole, all-hydrocarbon and PF benzyl) were 
incorporated in a peptide sequence derived from β3 integrin cytoplasmic tail. CD 
spectroscopy was used to compare peptides 7 (lactam), 10 (triazole) and 11 
(hydrocarbon), revealing that all linkers gave rise to similar helical content. Peptide 10, 
containing the triazole linker, had the greatest percentage helicity (62%) of the three 
peptides studied, displaying a [θ]222/[θ]208 ratio (0.95) closest to 1. These results differ 
from the study by de Araujo et al.8 in which model alanine rich peptides with lactam 
linkers produced the greatest helical structure, when compared to triazole and all-
hydrocarbon linked peptides. The difference between these two studies suggests that 
peptide sequence must be considered when determining which type of linker will create 
the largest helical content.  
Cellular uptake studies of fluorescein tagged peptides F7, F10 and F11, identified 
peptide F11 (all-hydrocarbon) as the peptide that displayed the highest levels of cellular 
uptake. Peptide F10 (triazole linker), displayed greater cellular uptake than the linear 
peptide (Fβ3MP(722-739)), whereas the lactam peptide F7 resulted in lower levels of 
cellular uptake than Fβ3MP(722-739) as determined by FACS analysis. The basis of the 
differences between the cellular uptake of F11, F10 and F7 appears to be affected by 
both helicity of the peptide and the polarity of the side chain linker. The least polar of 
the linkers was the all-hydrocarbon linker, this gave rise to the peptide with the greatest 
cellular uptake. The amide linker of F7 is less polar than the triazole linker of F10, which 
would suggest that F7 should have greater cellular uptake, however this is not the case 
with F10 displaying greater cellular uptake. These results may be due to F10 having 
greater helical content than F7. In this case it appears the helicity of the peptide may be 
more significant than polarity in determining cellular uptake.  
The effect of charge on cellular uptake of integrin-derived peptides was investigated 
using all-hydrocarbon linkers. This study suggests an increase in localised positive 
charge at the N-terminus of the peptide (F15), achieved by addition of three arginine 
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residues, resulted in a far greater increase in cellular uptake than distributed positive 
charge within the peptide sequence (F15 vs F16).  
The PF benzyl linker was incorporated into the 18-residue integrin-derived sequence, 
12, equivalent to the lactam, triazole and all-hydrocarbon linked peptides, 7, 10 and 11. 
Helicity could not be directly compared with 7, 10 and 11 as the CD spectrum of 12 was 
complicated by absorption due to the perfluorobenzyl group, which masks any 
minimum at 222 nm used to determine helicity. Two previously reported approaches 
were used to determine the helicity of 12; subtraction of the PF group absorption at 
222 nm from the ellipticity of 12, and comparison of the ellipticity of 12 with β3MP(722-
739) at 195 and 208 nm. These approaches provided significantly different results, with 
no clear evidence that either method was more valid. Thus, in this case CD spectroscopy 
is not an appropriate method for quantifying helicity of PF benzyl linked peptides. NMR 
structural studies would likely provide a clearer indication of helical structure. Cellular 
uptake of the PF benzyl linked peptide was visualised using confocal microscopy 
indicating cellular uptake of the peptide. However, FACS analysis is required for a 
quantitative comparison to other peptide linkers.  
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4.1.1 General Information 
Solvents and reagents were of reagent grade or higher and used as supplied. 9-
Fluorenylmethoxycarbonyl (Fmoc) protected L-amino acids, Fmoc-Trp(OtBu)-OH, Fmoc-
Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Asp(Opip)-OH, Fmoc-Cys(Trt)-
OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(Opip)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Mmt)-OH, 
Fmoc-Phe-OH, Fmoc-Pra-OH and Fmoc-His(Trt)-OH, as well as Boc-L-Lys-OH, N-
[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide (HATU), and O-(1H-6-
chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HCTU) 
were purchased from Chem-Impex International (Wooddale, IL, USA). 
Dimethylformamide (AR grade) (DMF), N-methyl-2-pyrrolidone (NMP), 
dichloromethane (DCM), and piperidine were purchased from Merck (Darmstadt, 
Germany). Acetonitrile (HPLC grade) and methanol (HPLC grade) were purchased from 
Scharlau (Sentmenat, Barcelona, Spain). Trifluoroacetic acid (TFA), trifluoroethanol 
(TFE) (NMR grade), and diisopropylethylamine (DIPEA) were purchased from Alfar Aesar 
(Ward Hill, MA, USA). N-hydroxybenzotriazole (HOBt), (S)-N-Fmoc- ξ-(4’pentenyl) 
alanine, Fmoc-Lys(N3)-OH, and Fmoc Rink amide resin were purchased from, GL 
Biochem (Shanghai, China), Okeanos, (Japan), ChemPep Inc. (Wellington, USA), and 
Agilent (Santa Clara, CA, USA) respectively .All other reagents were purchased from 
Sigma-Aldrich (USA, or Castle Hill, NSW, Australia). 
 
4.1.2 Physical and spectroscopic techniques 
4.1.2.1 Mass spectrometry (MS) and Nuclear magnetic resonance (NMR) spectroscopy 
characterisation. 
High resolution mass spectra (HMRS) were acquired with an Agilent 1260 infinity TOF 
LC/MS 6230, running Agilent Mass Hunter software. The process of elongation was 
monitored during peptide synthesis using an electrospray ionization ion trap mass 
spectrometer (Bruker, HCT mass spectrometer).1H NMR, 13C NMR and 2D spectra were 
recorded using the Varian Oxford NMR 600 MHz, with Agilent DD2 console. Software 
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running on the spectrometers was Agilent VnmrJ 4.2. Chemical shifts are reported in 
parts per million (ppm) on the δ scale.  
4.1.2.2 Circular dichroism (CD) analysis  
Samples were prepared in 10 mM phosphate buffer, containing 0% or 10% TFE with the 
final peptide concentration of approximately 25 μM. The exact concentrations of 
peptides were determined by the UV absorption of tyrosine residue at 280 nm which 
was used to calculate molar ellipticity.  
CD measurements for all peptides were performed using a Jasco J-815 circular 
dichroism spectropolarimeter (Jasco Corp., Japan), calibrated with d-10-
camphorsulfonic acid. The quartz cell temperature of 25°C was stabilised using a Peltier 
temperature controller. Secondary spectra for all peptides were obtained between 
wavelengths of 190-260 nm under the same parameters, where scan speed was 
10 nm/minute, bandwidth was 1.0 nm and the resolution was 1 nm with a 1 second 
response. A 0.1 mm quartz cuvette were used, and three repeat scans were compiled 
to generate the average spectra. The CD signal resulting from the solvent alone was 
subtracted from the spectrum of each peptide solution. The results were evaluated 
using the Jasco Spectra Manager and any remaining noise in the spectra was smoothed 
using Savitzky-Golay convolution (width: 9). Data were converted to ellipticity 
(deg.cm2.dmol-1.residue-1) according to the equation 11. 
The α-helical content of each peptide was determined from the mean residue molar 
ellipticity at 222 nm.  
[θ] = θ /(10 l c n) eq. 1 
Where [θ] is the mean residue molar ellipticity (deg.cm2.dmol-1), θ is ellipticity (mdeg), 
l is the path length (cm), c is the concentration (mol L-1) and n is the number of residues. 
Percent helicity was calculated from the ratio [θ]222/[θ]max, where 
[θ]max = (−44 000 + 250T)(1 − k/n) eq. 2 
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Where [θ]max is the maximum mean residue molar ellipticity (deg.cm2.dmol-1), T is the 
temperature (°C), k is the number of non-hydrogen-bonded peptide carbonyls. For free 
N-terminal peptide it has been suggested a value of 4, n is number of residues1. 
For our system we used [θ]max = −23 400 for k = 4.0 and n = 18 (number of amino acid 
residues in the peptide). 
Table 4-1: Molar ellipticity [θ] (deg cm2 dmol-1 residue-1) at 222 nm, percentage helicity and 
ratios of ellipticity at 222 nm/208 nm for β3MP(722-739) peptides, 7, 10 and 11 determined 
from CD data acquired in 10% TFE, 10 mM phosphate buffer (pH 6.5, 25oC). 
a Molar ellipticity [θ] (deg cm2 dmol-1 residue-1) at 222 nm, acquired from CD data 
b percent helicity 
c ratios of ellipticity at 222 nm/208 nm  
 
4.1.3 Purification and isolation techniques  
4.1.3.1 Purification and analysis by reverse phase high performance liquid 
chromatography (RP-HPLC) 
Peptides were purified by RP-HPLC, performed using a Gilson semi prep system (GX-271 
liquid handler, UV/VIS-155, and 322-pump) fitted with a Supleco (C18, 300 Å, 5 μm, 
10 mm x 250 mm) column. Peptides were generally purified with a gradient of 20-45% 
ACN/H2O with 0.1% TFA over 25 minutes Carboxyfluorescein labelled peptides were 
purified using a gradient of 25-50% ACN/H2O with 0.1% TFA over 25 minutes. Fractions 
were collected where absorbance at 215 nm exceeded 50 mV.  
Peptide [θ]222a Helicityb [θ]222/[θ]208c 
β3MP(722-739) -10691.6 36% 0.69 
7 -19073.7 65% 0.79 
10 -20789.1 71% 1.18 
11 -19744.9 67% 0.88 
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Peptide purity was determined using analytical RP-HPLC, performed on an Agilent 1260 
system fitted with an analytical (C18,  300 Å, 5 μm, 4.6 mm x 150 mm) column. The 
eluents were 0.1% aqueous TFA and 0.1% TFA in acetonitrile. 
 
4.1.3.2 Lyophilisation 
Synthetic peptides were lyophilised on a Christ Alpha 2-4 LSC freeze-dryer. 
 
4.1.4 General Procedure I: Manual SPPS 
Where stated, peptide elongation was performed manually on Fmoc-Rink Amide resin 
on a 0.1 mmol scale, using the Fmoc/tBu strategy2. Deprotection: The Nα-Fmoc group 
was removed by treatment of the resin with a solution of 20% v/v piperidine in DMF 
containing HOBt (0.1 M) for 10 minutes. Amino acid coupling: The Nα-Fmoc protected 
amino acid (5 equiv.) was pre-activated with a solution of HATU in DMF 
(5 equiv., 0.45 M) and DIPEA (neat) (10 equiv.) for 2-10 minutes at rt. The activated 
solution was added to the resin and the mixture was left for 1 hr at rt. The solution was 
drained, and the resin was washed with DMF (3 x 5 ml), DCM (3 x 5 ml) and DMF 
(3 x 5 ml). Coupling reactions were monitored via the TNBSA test3 for primary amines. 
Unusual amino acid couplings: Nα-Fmoc protected Fmoc-Lys(Mmt)-OH, Fmoc-
Asp(Opip)-OH, Fmoc-Glu(Opip)-OH), Fmoc-Pra-OH, Fmoc-L-Nle (εN3)-OH were coupled 
as detailed below. Nα-Fmoc protected amino acid (2.5 equiv.) was pre-activated with a 
solution of HATU in DMF (2.5 equiv.) and DIPEA (neat) (5 equiv.) for 2 minutes at rt. The 
activated solution was added to the resin and the mixture was left for 16 hrs at rt. The 
solution was drained, and the resin was washed with DMF (3 x 5 ml), DCM (3 x 5 ml) and 
DMF (3 x 5 ml). To confirm reaction had reached completion 10 mg of resin was cleaved 
(general method III), and the peptide analysed by HPLC and ESI-MS. If the reaction was 
found to be incomplete a second coupling was performed with fresh reagents.  
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4.1.5 General procedure II: Automated peptide synthesis 
Where stated, automated peptide synthesis was carried out on a Liberty Microwave 
Peptide Synthesiser (CEM Corporation) using the Fmoc/tBu strategy2. Deprotection: The 
Nα-Fmoc group was deprotected before addition of Nα-Fmoc protected amino acids by 
consecutive additions of 20% v/v piperidine in DMF for 30 seconds and 3 minutes. The 
maximum microwave power was set to 25 W and the maximum temperature was set 
to 75°C. Resin was then washed with DMF (4 x 7 ml). Amino acid couplings: The Nα-
Fmoc protected amino acid in DMF (5 equiv., 0.2 M), HATU in DMF (4.5 equiv., 0.45 M) 
and DIPEA in NMP (10 equiv., 2 M) were added to the rink amide resin and subjected to 
25 W microwave irradiation for 6 minutes. Each coupling was performed twice with a 
maximum temperature of 50°C for both couplings. The exception was Fmoc-Arg(Pbf)-
OH, which was coupled for 1500 seconds at rt, followed by coupling for 300 seconds at 
25 W microwave irradiation and the maximum temperature of 75°C. 
 
4.1.6 General Procedure III: Cleavage of Peptides from Rink Amide Resin 
Cleavage of the peptide from the resin was performed using 2.5% triisopropylsilane 
(TIPS), 2.5% 2,2′-(ethylenedioxy)diethanethiol (DODT) and 2.5% water in TFA (1 ml per 
50 mg) for 2 hrs. Half the TFA was removed under nitrogen, and peptide was 
precipitated by addition of diethyl ether. The suspended peptide was isolated by 
centrifugation and residue dissolved in 30% acetonitrile in water and lyophilised.  
 
4.1.7 General Procedure IV: Peptide cyclisation for lactam bridged peptides 
Fully protected resin bound peptide (0.1 mmol) was successively washed with DMF 
(5 x 5 ml) and DCM (5 x 5 ml). A solution of DCM, TFA, TIPS (94:1:5, 5 ml) was added to 
the resin to selective remove the side chain protecting groups, methoxytrityl (Mmt) and 
2-phyenyl isopropyl oxy (Opip) of lysine (Lys) and aspartic acid (Asp)/ glutamic acid (Glu) 
respectively. The solution was stirred for 2 minutes, and then washed with DCM 
(5 x 5 ml). This procedure was repeated 10 times. The resin was then washed with DCM 
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(5 x 5 ml) and DMF (5 x 5 ml). The resin bound peptide was treated with PyBOP (52 mg, 
0.1 mmol,) and DIPEA (86 μl, 0.5 mmol,) in DMF. After 18 hrs the reagents were 
removed by filtration, and a sample of the resin (10 mg) was cleaved (general method 
III) and analysed by HPLC and ESI-MS. If the cyclisation had not reached completion, the 
coupling was repeated with fresh reagents. The overall cyclisation reaction varied from 
1 to 3 days as shown in each example below.  
 
4.1.8 General Procedure V: Cyclisation of Hydrocarbon Linked Peptides.  
Dried resin bound linear peptide precursors (0.05 mmol) was swollen in anhydrous DCM 
(6 ml). Lithium chloride dissolved in anhydrous DMF (4M, 0.4 ml) was added to solution, 
followed by the addition of 2nd generation Grubbs’ catalyst (11 mg, 12.5 μmol). The 
reaction mixture was then heated at 100 W μwave, with the maximum temperature set 
at 80°C for 1 hr.  
 
4.1.9 General Procedure VI: Carboxyfluorescein Labelling 
Resin bound peptide (0.1 mmol) was swollen in DCM: DMF (1:1, 5 ml). Fmoc- β-alanine 
(155 mg, 0.5 mmol) dissolved in DMF (2 ml), was pre-activated by addition of HCTU in 
DMF (1 ml, 0.5M) and DIPEA (174 μl) for 2 minutes. The resin was washed with DMF (5 
x 5 ml) followed by addition of pre-activated Fmoc- β-alanine, and allowed to react for 
1 hr. The resin was then drained, followed by a second addition of pre-activated Fmoc- 
β-alanine to the resin which was allowed to react for 1 hr. Na-Fmoc protecting group 
was removed via treatment of the resin bound peptide with piperidine (20%) and HOBt 
(0.1 M) in DMF (5 ml) for 10 minutes. The resin was then washed with DMF (5 x 5 ml), 
DCM (2 x 5 ml) and DMF (2 x 5 ml). 5(6)-Carboxyfluorescein (95 mg, 0.25 mmol) was 
dissolved in NMP (0.5 ml) and added to PyBOP (130 mg, 0.25 mmol) dissolved in NMP 
(0.5 ml). DIPEA (87 μl, 0.5 mmol) was then added and the reaction mixture was allowed 
to react for 2 minutes. The reaction mixture was then added to the resin and allowed 
to react for 18 hrs. Reagents were removed by filtration, and a sample of the resin 
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(10 mg) was cleaved (general method III) and analysed by HPLC and ESI-MS. If the 
cyclisation had not reached completion, the coupling was performed with fresh 
reagents. 
 
4.2 Experimental work described in Chapter 2 
4.2.1 Peptide β3MP(722-735) (NH2-HDRKEFAKFEEDRA-CONH2) 
Resin bound peptide was synthesised on rink amide resin on a 0.1 mmol scale. The initial 
deprotection and addition of the C-terminal Fmoc-Ala-OH to the resin was performed 
manually according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from R(734) to R(724), following methods described in general 
procedure II. Manual addition of final residues D(723) and H(722) was performed 
according to general procedure I. The peptide with free N-terminal was then cleaved 
according to general procedure III, and the crude peptide was purified by RP-HPLC. Pure 
fractions were collected and lyophilised to afford β3MP(722-735) as a white powder. 
LCMS (ESI+) [M+2H]+2 calculated for [C78H119N25O24]:895.9509;observed: 895.9496 m/z. 
 
Figure 4-1: RP-HPLC trace of purified β3MP(722-735) monitoring at a wavelength 
of 215 nm with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.2.2 Peptide 1 (NH2-HDRKEFAK*FEED*RA-CONH2) 
Resin bound peptide was synthesised on rink amide resin on a 0.1 mmol scale according 
to methods described in the general procedure I from A(735)-D(723). Uncommon amino 
acids Fmoc-Asp(Opip)-OH and Fmoc-Lys(Mmt)-OH were coupled at positions 733 and 
729, in accordance with coupling uncommon amino acids. Cyclisation of the resin bound 
Fmoc protected peptide was performed according to general procedure IV, followed by 
the addition of the final residue H(722) following methods described in general 
procedure I. The completed peptide was cleaved from the resin according to general 
procedure III. The crude peptide was purified by RP-HPLC, pure fractions were collected 
and lyophilised to afford 1 as a white powder. LCMS (ESI+) m/z calculated for 





Figure 4-2: RP-HPLC trace of purified 1 monitoring at a wavelength of 215nm with 
a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.2.3 Peptide 2 (NH2-HDRKEFAK*FEEE*RA-CONH2) 
Resin bound peptide was synthesised on rink amide resin on a 0.1 mmol scale according 
to methods described in the general procedure I from A(735) to D(723). Fmoc-
Glu(Opip)-OH and Fmoc-Lys(Mmt)-OH were coupled at positions 733 and 729 in 
accordance with coupling uncommon amino acids. Cyclisation of the Fmoc protected 
peptide was performed using general procedure IV followed by the manual addition of 
final residue H(722) following methods described in general procedure I. The completed 
peptide was cleaved from the resin according to general procedure III. The crude 
peptide was purified by RP-HPLC, pure fractions were collected and lyophilised to afford 
2 as a white powder. LCMS (ESI+) m/z calculated for C78H117N25O23: 1771.8754 (average 






Figure 4-3: RP-HPLC trace of purified 2 monitoring at a wavelength of 280nm with 
a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.2.4 Peptide 3 (NH2-HDRK*EFAD*FEEERA-CONH2) 
Resin bound peptide was synthesised on rink amide resin on a 0.1 mmol scale. The initial 
deprotection of the resin and addition of the C-terminal Fmoc-Ala-OH was performed 
manually according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from R(734) to F(730), following general procedure II. Manual 
elongation of the peptide up to D(723) was performed using methods described in 
general procedure I, including coupling of uncommon amino acids Fmoc-Asp(Opip)-OH 
and Fmoc-Lys(Mmt)-OH at positions 729 and 725. Cyclisation of the Fmoc protected 
peptide was performed using general procedure IV, followed by the addition of final 
residue H(722) following methods described in general procedure I. The completed 
peptide, with Nα-terminal Fmoc deprotected, was cleaved from the resin according to 
general procedure III. The crude peptide was purified by RP-HPLC, pure fractions were 
collected and lyophilised to afford 3 as a white powder. LCMS (ESI+) m/z calculated for 
C75H110N24O24: 1730.8125 (average isotopes); observed: m/z 866.41 ([M+3H]+3) 577.94 
([M+4H]+4).  
 
Figure 4-4: RP-HPLC trace of purified 3 monitoring at a wavelength of 280nm with 
a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
C h a p t e r  4   | 106 
 
4.2.5 Peptide 4 (NH2-HDRE*EFAK*FEEERA-CONH2) 
Resin bound peptide was synthesised on rink amide resin on a 0.1 mmol scale. The initial 
deprotection of the resin and addition of the C-terminal Fmoc-Ala-OH was performed 
according to general procedure I. Automated peptide synthesis was used to elongate 
the sequence from R(734) to F(730), following general procedure II. Manual elongation 
of the peptide to D(723) was performed using methods described in general procedure 
I, including coupling of uncommon amino acids Fmoc-Glu(Opip)-OH and Fmoc-
Lys(Mmt)-OH in positions 729 and 735. Cyclisation of the Fmoc protected peptide was 
performed using general procedure IV, followed by the addition of final residue H(722) 
following methods described in general procedure I. The completed peptide, with Nα-
terminal Fmoc deprotected, was cleaved from the resin according to general procedure 
III. The crude peptide was purified by RP-HPLC, pure fractions were collected and 
lyophilised to afford 4 as a white powder. LCMS (ESI+) m/z calculated for C76H112N24O24: 
1744.8281 (average isotopes); observed: m/z 873.41 ([M+3H]+3) 582.61 ([M+4H]+4).  
 
Figure 4-5: RP-HPLC trace of purified 4 monitoring at a wavelength of 280nm with 
a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes 
C h a p t e r  4   | 107 
 
4.2.6 Peptide 5 (NH2-HDRD*EFAK*FEEERA-CONH2) 
Resin bound peptide was synthesised on rink amide resin on a 0.1 mmol scale. The initial 
deprotection of the resin and addition of the C-terminal Fmoc-Ala-OH was performed 
according to general procedure I. Automated peptide synthesis was used to elongate 
the sequence from R(734) to F(730), following general procedure II. Manual elongation 
of the peptide to D(723) was performed using methods described in general 
procedure I, including coupling of uncommon amino acids, Fmoc-Asp(Opip)-OH and 
Fmoc-Lys(Mmt)-OH at positions 729 and 725. Cyclisation of the resin bound Fmoc 
protected peptide was performed according to general procedure IV, followed by the 
addition of final residue H(722) according to methods described in general procedure I. 
The completed peptide with free Nα-terminal, was cleaved from the resin following 
general procedure III. The crude peptide was purified by RP-HPLC, pure fractions were 
collected and lyophilised to afford 5 as a white powder. LCMS (ESI+) m/z calculated for 
C75H110N24O24: 1730.81248 (average isotopes); observed: m/z 866.41 ([M+3H]+3) 577.92 
([M+4H]+4).  
 
Figure 4-6: RP-HPLC trace of purified 5 monitoring at a wavelength of 280nm with 
a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes 
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4.2.7 Peptide β3MP(722-739) (NH2-HDRKEFAKFEEDRARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection and coupling of C-terminal Fmoc-Trp(OtBu)-OH to the resin was 
performed manually according to methods described in general procedure I. 
Automated peptide synthesis was used to elongate the sequence from K(738) to R(724) 
according to general procedure II. Manual addition of final residues D(723) and H(722) 
was then completed in accordance with general procedure I. The desired peptide, with 
free Nα-terminal, was cleaved from the resin according to general procedure III. The 
crude peptide was purified by RP-HPLC, pure fractions were collected and lyophilised to 
afford β3MP(722-739) as a white powder. HRMS (ESI+) [M+3H]+3 calculated for 





Figure 4-7: RP-HPLC trace of purified β3MP(722-739) monitoring at a wavelength 
of 280nm with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.2.8 Peptide 6 (NH2-HDRKEFAK*FEED*RARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection of the resin and addition of the C-terminal Fmoc-Trp(OtBu)-OH was 
performed according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from K(738) to R(734) according to general procedure II. The 
peptide was then elongated manually according to general procedure I, including 
coupling of uncommon amino acids, Fmoc-Asp(Opip)-OH and Fmoc-Lys(Mmt)-OH at the 
positions 733 and 729. Cyclisation of the resin bound Fmoc protected peptide was 
performed using general procedure IV, followed by the addition of final residue H(722) 
following methods described in general procedure I. The completed peptide, with free 
Nα-terminal Fmoc, was cleaved from the resin according to general procedure III. The 
crude peptide was purified by RP-HPLC, pure fractions were collected and lyophilised to 
afford 6 as a white powder. HRMS (ESI+) [M+3H]+3 calculated for [C103H154N34O27]: 


























Figure 4-8: RP-HPLC trace of purified 6 monitoring at a wavelength of 280nm with 
a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.2.9 Peptide 7 (NH2-HDRK*EFAD*FEEERARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection of the resin and addition of the C-terminal Fmoc-Trp(OtBu)-OH was 
performed according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from K(738) to F(730), according to general procedure II. The 
peptide was then elongated manually to D(723) according to general procedure I, 
including coupling of uncommon amino acids, Fmoc-Asp(Opip)-OH and Fmoc-Lys(Mmt)-
OH at positions 729 and 725. Cyclisation of the resin bound Fmoc protected peptide was 
performed according to general procedure IV followed by the addition of final residue 
H(722) in accordance with methods described in general procedure I. The completed 
peptide, with free Nα-terminal, was cleaved from the resin according to general 
procedure III. The crude peptide was purified by RP-HPLC, pure fractions were collected 
and lyophilised to afford 7 as a white powder. HRMS (ESI+) [M+4H]+4 calculated for 


























Figure 4-9: RP-HPLC trace of purified 7 monitoring at a wavelength of 280nm with 
a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.2.10 Peptide 8 (NH2-HDRKEFKK*FED*ERARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection of the resin and addition of the C-terminal Fmoc-Trp(OtBu)-OH was 
performed according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from K(738) to E(733) was performed according to general 
procedure II. The peptide was then elongated manually to D(723) according to general 
procedure I, including coupling of uncommon amino acids, Fmoc-Asp(Opip)-OH and 
Fmoc-Lys(Mmt)-OH at the positions 734 and 729. Cyclisation of the resin bound Fmoc 
protected peptide was performed using general procedure IV followed by the addition 
of final Fmoc- residue H(722) according to methods described in general procedure I. 
The completed peptide, with free Nα-terminal, was cleaved from the resin according to 
general procedure III. The crude peptide was purified by RP-HPLC, pure fractions were 
collected and lyophilised to afford 8 as a white powder. HRMS (ESI+) [M+4H]+4 



























Figure 4-10: RP-HPLC trace of purified 8 monitoring at a wavelength of 280nm 
with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.2.11 Peptide 9 (NH2-HDK*KEFD*KFEEERARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection of the resin and addition of the C-terminal Fmoc-Trp(OtBu)-OH was 
performed according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from K(738) to F(730) according to general procedure II. The 
peptide was then elongated manually to D(723) according to general procedure I, 
including coupling of uncommon amino acids, Fmoc-Asp(Opip)-OH and Fmoc-Lys(Mmt)-
OH at positions 728 and 724. Cyclisation of the Fmoc protected peptide was performed 
using general procedure IV followed by the addition of final Fmoc-His-OH residue. The 
completed peptide, with Nα-terminal Fmoc deprotected, was cleaved from the resin 
according to general procedure III. The crude peptide was purified by RP-HPLC, pure 
fractions were collected and lyophilised to afford 9 as a white powder. HRMS (ESI+) 





Figure 4-11: RP-HPLC trace of purified 9 monitoring at a wavelength of 280nm 
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4.2.12 NMR Titrations 
15N-1H HSQC titrations of U-15N-labeled talin F3 domain (0.1 mM), with linear peptide 
β3MP(722-739) and linked peptides 6-9 were performed by Dr Kate Wegener according 
to protocols described in Keeling et.al.4  
 
4.2.13 NMR structure determination 
Peptide structures of linear peptide β3MP(722-739), and linked peptides 6-9 were 
calculated by Dr Kate Wegener using a version of ARIA 2.3, modified to deal with lactam 
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Figure 4-12: Binding curves displaying the change in chemical shift (Δδ) with increasing peptide 
ligand concentration (μM), for the ten most shifted peaks in each HSQC spectrum. Residue 

















Figure 4-13: NOE connectivity maps. Ambiguous NOEs are indicated in grey 
 
4.2.14 Proteolysis 
Proteolysis experiments were carried out in collaboration with Dr Okki Cho, (The 
University of Adelaide, Australia). 
Purified peptide β3MP(722-739), 7,and 8 (110 μM, 50 μl) was combine with of α-
chymotrypsin (Sigma Aldrich, 500 nM, 5 μl) and incubated it in Tris HCl (50 mM), pH 7.5, 
at rt, for the times specified for each peptide. The reaction was quenched by addition 
of 20% TFA in water (3.3 μl), and the samples of digested peptide were frozen to prevent 
Peptide 8 
Peptide 9 
C h a p t e r  4   | 118 
 
further degradation. Samples were defrosted for analysis and aliquots (50 μl) were 
injected on eclipse XDB-C18 column (4.6 x 150 mm, 5 μm, Agilent System 1260 Infinity) 
coupled to a mass spectrometry (Bruker HCT, Germany). The samples were eluted with 
a gradient of 1-100% ACN/H2O with 0.1% formic acid over 20 minutes. Spectra were 
analysed using Hystar software (3.1) and the remaining substrate was quantified using 
extracted ion mass chromatogram. Relative protein concentrations were determined 
from the area under the curve (Table 4-2, Table 4-3, and Figure 4-14) 
 
Table 4-2: Raw data collected for proteolysis of β3MP(722-739) by chymotrypsin. 
Time (minutes) % intact peptide 
remaining 
% intact peptide 
remaining 
% intact peptide 
remaining 
0 1 1 1 
10 0.552 0.729 0.481 
20 0.335 0.504 0.406 
30 0.112 0.323 0.265 
45 0.117 0.146 0.061 
60 0.018  0.087 
90 0.025  0.018 
























Figure 4-14: Left, the extracted ion chromatogram for β3MP(722-739) (light blue), and 
hydrolysis products, shown in blue and red. Right, Mass spectrum of β3MP(722-739) 778 amu 
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Table 4-3: Raw data collected for proteolysis of peptide 7 by chymotrypsin 
Time (minutes) % intact peptide 
remaining 
% intact peptide 
remaining 
% intact peptide 
remaining 
0 1 1 1 
45 1.087 0.974 0.956 
60 1.033 0.952 0.899 
90 1.063 0.942 0.909 
180 1.061 1.016 0.978 
240 0.901 0.839 0.9 





























Figure 4-15: Left, the extracted ion chromatogram for peptide 7. Right, Mass spectrum of 
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Table 4-4: Raw data collected for proteolysis of peptide 6 by chymotrypsin 
Time (minutes) % intact peptide 
remaining 
% intact peptide 
remaining 
% intact peptide 
remaining 
0 1 1 1 
10  0.857 0.766 
30  0.858 0.662 
45 0.589 0.757 0.597 
60 0.447  0.548 
90 0.615 0.675 0.51 
120 0.367 0.696 0.201 
180 0.342 0.57  
240 0.347 0.586  
1080  0.341  

























Figure 4-16: Left, the extracted ion chromatogram for peptide 6 (light blue) and hydrolysis 
product (orange). Right, Mass spectrum of peptide 6 767 amu [M+4]+4, 576 amu [M+5]+5, 461 
amu [M+6]+6(top) and hydrolysis product (bottom). 
 
4.3 Experimental work described in Chapter 3 
Peptide β3MP(722-739) (NH2-HDRKEFAKFEEDRARAKW-CONH2) 
β3MP(722-739) was synthesised as described previously (See 4.2.1,) 
 
Peptide 7 (NH2-HDRK*EFAD*FEEDRARAKW-CONH2) 
Peptide 7 was synthesised as described previously (4.2.9) 
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4.3.1 Peptide 10 (NH2-HDR[Nle(εN3)]*EFA[Pra]*FEEDRARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection and coupling of the C-terminal Fmoc-Trp(OtBu)-OH were performed 
manually according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from K(738) to F(730) according to general procedure II. The 
peptide was then elongated manually from Pra(729) – H(722) according to general 
procedure I, which included coupling of uncommon amino acids Fmoc-L-Pra-OH and 
Fmoc-L- Nle(εN3)-OH in the positions 729 and 727. The completed peptide, with Nα-
terminal Fmoc deprotected, was cleaved from the resin according to general procedure 
III. The crude peptide was purified by RP-HPLC, pure fractions were collected and 
lyophilised to afford the linear peptide precursor of 10 as a white powder. Purified linear 
peptide precursor was dissolved in water and tert-butanol (2:1, 1 mg/ml), followed by 
addition of ascorbic acid (4.4 eq) and CuSO4 (4.4 eq). The reaction mixture was stirred 
for 18 hrs. The cyclised peptide was purified by RP-HPLC. Pure fractions were lyophilised 
to afford 10 as a white powder. LCMS (ESI+) m/z calculated for C103H149N35O28: 
2324.1311; observed: m/z 775.7145 ([M+3H]+3) (expected: 775.7104). 
 
 
Figure 4-17: RP-HPLC trace of purified 10 monitoring at a wavelength of 280nm 
with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.2 Peptide 11 (NH2-HDRX*EFAX*FEEDRARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection and addition of the C-terminal Fmoc-Trp(OtBu)-OH to the resin was 
performed according to general procedure I. Automated peptide synthesis was used to 
elongate the sequence from K(738) to F(730) according to general procedure II. The 
peptide was then elongated manually according to general procedure I, including 
coupling of uncommon amino acids (S)-N-Fmoc- ξ-(4’pentenyl) alanine (X) at positions 
729 and 727. Cyclisation of the Fmoc protected peptide was performed following the 
general procedure V. The Nα-terminal Fmoc group was deprotected as described in 
general procedure I and the completed peptide was cleaved from the resin according 
to general procedure III. The crude peptide was purified by RP-HPLC, pure fractions 
were collected and lyophilised to afford 11 as a white powder. LCMS (ESI+) m/z 
calculated for C106H156N32O28: 2325.1767 (average isotopes); observed: m/z 776.0670 
([M+3H]+3). 
 
4.3.3 Peptide 12 (NH2-HDRC*EFAC*FEEDRARAKW-CONH2) 
The resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin. The 
initial deprotection and addition of the Fmoc-Trp(OtBu)-OH to the resin was performed 
Figure 4-18: RP-HPLC trace of purified 11 monitoring at a wavelength of 
280nm with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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according to general procedure I. Automated peptide synthesis was used to elongate 
the sequence K(738) to R(724) according to general procedure II. The final residues 
D(723) and H(722), were incorporated according to general procedure I. The Nα-
terminal Fmoc group was deprotected as described in general procedure I and the 
peptide was cleaved from the resin according to general procedure III. The crude 
peptide was purified by RP-HPLC, pure fractions were collected and lyophilised to afford 
the linear precursor of 12 as a white powder. The linear precursor (1 eq), 
hexafluorobenzene (25 eq), 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris base) (13 
eq) and LiCl (5 eq) were dissolved in DMF (1 mg/ml) and sonicated at room temperature 
for 30 minutes, the reaction mixture was then allowed to react for a further 18 hrs. 
Solvent was removed in vacuo and the residue was dissolved in water with 0.1% TFA. 
The crude peptide was purified by RP-HPLC, pure fractions were collected and 
lyophilised to afford 12 as a white powder. LCMS (ESI+) m/z calculated for 
C104H142F4N32O28S2: 2427.0049; observed: m/z 810.0081 ([M+3H]+3). 
 
 
Figure 4-19: RP-HPLC trace of purified 12 monitoring at a wavelength of 280nm 
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4.3.4 Peptide CF–NYAD-1 (CF-βAla-ITFX*DLLX*YYGP -CONH2)  
CF–NYAD-1 peptide was based on the NYAD peptide synthesised by Zhang.et.al5. The 
resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin according 
to methods described in the general procedure I, including couplings of uncommon 
amino acid (S)-N-Fmoc- ξ-(4’pentenyl) alanine (X). Cyclisation of the Fmoc protected 
peptide was performed following the general procedure V. The Nα-terminal Fmoc was 
then deprotected, and the peptide was labelled as described in the general procedure 
VI. The peptide was then cleaved from the resin and the crude peptide purified by RP-
HPLC. Pure fractions were collected and lyophilised to afford CF–NYAD-1 as a yellow 
powder. LCMS (ESI+) m/z calculated for C98H121N13O25: 1863.8647 (average isotopes); 































Figure 4-20: RP-HPLC trace of purified CF-NYAD-1 monitoring at a 
wavelength of 280nm with a gradient of 0-100% ACN/H2O with 0.1% TFA 
over 20 minutes. 
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4.3.5 Peptide Fβ3MP(722-739) (CF-βAla-HDRKEFAKFEEDRARAKW-CONH2) 
Resin bound peptide was synthesised as described previously for resin bound peptide 
β3MP(722-739). The peptide was fluorescently labelled as described in the general 
procedure VI, before the peptide was cleaved from the resin according to general 
procedure III. The crude peptide was purified by RP-HPLC, pure fractions were collected 
and lyophilised to afford Fβ3MP(722-739) as a yellow powder. LCMS (ESI+) m/z 
































Figure 4-21: RP-HPLC trace of purified Fβ3MP(722-739) monitoring at a 
wavelength of 280nm with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 
minutes. 
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4.3.6 Peptide F7 (CF-βAla-HDRK*EFAD*FEEDRARAKW-CONH2) 
Resin bound peptide was synthesised as described previously for resin bound peptide 
7. The peptide was labelled as described in the general procedure VI, before the peptide 
was cleaved from the resin according to general procedure III. The crude peptide was 
purified by RP-HPLC, pure fractions were collected and lyophilised to afford F7 as a 
yellow powder. LCMS (ESI+) m/z calculated for C126H164N34O36: 2761.2906 (average 

































Figure 4-22: RP-HPLC trace of purified F7 monitoring at a wavelength of 280nm 
with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.7 Peptide F10 (CF-βAla-HDR[Nle(εN3)]*EFA[Pra]*FEEDRARAKW-CONH2) 
Resin bound peptide was synthesised as described previously for resin bound peptide 
10. The peptide was labelled as described in the general procedure VI before the 
peptide was cleaved from the resin according to general procedure III. Linear precursor 
of F10 was given as a yellow powder. LCMS (ESI+) m/z calculated for C126H164N34O36: 








Figure 4-23: RP-HPLC trace of purified F10 monitoring at a wavelength of 280nm 
with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
C h a p t e r  4   | 131 
 
4.3.8 Peptide F11 (CF-βAla-HDRX*EFAX*FEEDRARAKW-CONH2) 
Resin bound peptide was synthesised as described previously for resin bound peptide 
11. The peptide was labelled as described in the general procedure VI, before the 
peptide was cleaved from the resin according to general procedure III. The crude 
peptide was purified by RP-HPLC, pure fractions were collected and lyophilised to afford 
F11 as a yellow powder. LCMS (ESI+) m/z calculated for C130H171N33O35: 2754.2615 








Figure 4-24: RP-HPLC trace of purified F11 monitoring at a wavelength of 280nm 
with a gradient of 10-70% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.9 Peptide F12 (CF-βAla-HDRC*EFAC*FEEDRARAKW-CONH2) 
Linear peptide precursor of F12 was synthesised as described previously for resin bound 
linear peptide precursor of 12. The peptide was labelled as described in the general 
procedure VI, before the peptide was cleaved from the resin according to general 
procedure III. Linear peptide precursor of F12 was given as a yellow powder. Linear 
peptide precursor of F12, hexafluorobenzene, Tris base and LiCl were dissolved in DMF 
and sonicated at room temperature for 30 minutes, then allowed to react for a further 
18 hrs. The crude peptide was purified by RP-HPLC, pure fractions were collected and 
lyophilised to afford F12 as a yellow powder. C128H157N33O35S2: 2856.0897 (average 






Figure 4-25: RP-HPLC trace of purified F12 monitoring at a wavelength of 280nm 
with a gradient of 0-100% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.10 Peptide F13 (CF-βAla-HDRX*EFAX*FEEERA-CONH2) 
Resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin, from 
A(735) to D(723), according to methods described in the general procedure I; including 
couplings of uncommon amino acid, (S)-N-Fmoc- ξ-(4’pentenyl) alanine (X). Cyclisation 
of the Fmoc protected peptide was performed according to general procedure V. H(722) 
was incorporated according to general method I. The peptide with a free N-terminal 
was labelled following the general procedure VI. The peptide was then cleaved from the 
resin according to methods described in general method III. The crude peptide was 
purified by RP-HPLC, pure fractions were collected and lyophilised to afford F13 as a 







Figure 4-26: RP-HPLC trace of purified F13 monitoring at a wavelength of 280nm 
with a gradient of 0-100% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.11 Peptide F14 (CF-βAla-HNRX*EFAX*FQQERA-CONH2) 
Resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin, from 
A(735) to N(723), according to methods described in the general procedure I; including 
couplings of uncommon amino acid (S)-N-Fmoc- ξ-(4’pentenyl) alanine (X). Cyclisation 
of the Fmoc protected peptide was performed using general procedure V. H(722) was 
incorporated according to general method I. The peptide with a free N-terminal was 
labelled following the general procedure VI. The peptide was then cleaved rom the resin 
following general procedure III, and the crude peptide was purified by RP-HPLC. Pure 
fractions were collected and lyophilised to afford F14 as a yellow powder. LCMS (ESI+) 
m/z calculated for C104H135N27O28: 2209.9970 (average isotopes); observed: m/z 737.67 






Figure 4-27: RP-HPLC trace of purified F14 monitoring at a wavelength of 280nm 
with a gradient of 0-100% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.12 Peptide F15 (CF-βAla-HRRX*EFAX*FRRERA-CONH2) 
Resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin, from 
A(735) to N(723), according to methods described in the general procedure I; including 
couplings of uncommon amino acid (S)-N-Fmoc- ξ-(4’pentenyl) alanine (X). Cyclisation 
of the Fmoc protected peptide was performed using general procedure V. H(722) was 
incorporated according to general method I. The peptide with a free N-terminal was 
labelled following general procedure VI. The peptide was then cleaved from the resin 
and the crude peptide was purified by RP-HPLC, pure fractions were collected and 
lyophilised to afford F15 as a yellow powder. LCMS (ESI+) m/z calculated for 














Figure 4-28: RP-HPLC trace of purified F15 monitoring at a wavelength of 280nm 
with a gradient of 0-100% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.13 Peptide F16 (CF-βAla-RRRHNRX*EFAX*FQQERA-CONH2) 
Resin bound peptide was synthesised on a 0.1 mmol scale on rink amide resin, from 
A(735) to N(723), according to methods described in the general procedure I; including 
couplings of uncommon amino acid (S)-N-Fmoc- ξ-(4’pentenyl) alanine (X). Cyclisation 
of the Fmoc protected peptide was performed using general procedure V. H(722) and 
three arginine residues were incorporated at the N-terminal according to general 
method I. The peptide with a free N-terminal was labelled following general procedure 
VI. The peptide was then cleaved from the resin and the crude peptide was purified by 
RP-HPLC, pure fractions were collected and lyophilised to afford F16 as a yellow powder. 
LCMS (ESI+) m/z calculated for C121H169N39O31: 2678.3003 (average isotopes); observed: 
m/z 893.77 ([M+3H]+3) 671.58 ([M+4H]+4).  
 
 
Figure 4-29: RP-HPLC trace of purified F16 monitoring at a wavelength of 280nm 
with a gradient of 0-100% ACN/H2O with 0.1% TFA over 15 minutes. 
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4.3.14 Confocal Microscopy 
Proteolysis experiments were carried out in collaboration with Dr Briony Gliddon, 
(Molecular Signalling Laboratory Centre for Cancer Biology, SA Pathology, Adelaide, 
Australia). 
Confocal microscopy was used to visualise the cellular uptake of peptides Fβ3MP(722-
739), F7, F10 and F11 NIH3T3 cells (1.5x105) were seeded in a poly-L-lysine coated 12-
well plate overnight. A confluent monolayer of cells (70-80%) was used for experiment. 
The growth medium was removed, and the cells were washed with PBS followed by 
serum free medium. Serum free medium was then added to the cells for 3 hrs. The CF 
labelled peptides Cellular uptake of peptides Fβ3MP(722-739), F7, F10 and F11 (5 μM) 
were treated and incubated for 2 hrs at 37 °C. Cells were then washed with PBS (3x) and 
fixed by treatment with 4% paraformaldehyde.  Fixed cells were washed with PBS (x2). 
The cells were scanned and imaged under a Zeiss LSM510 laser scanning confocal 
microscope (Zeiss). 
 
4.3.15 Fluorescence-activated cell sorting (FACS) 
FACS analysis used to compare cellular uptake of peptides were carried out in 
collaboration with Dr Okki Cho, (The University of Adelaide, Australia). 
Cellular uptake of the peptides Fβ3MP(722-739), F7, F10, F11 and F13-F16, were 
investigated in NIH3T3 cells (mouse embryonic fibroblast, kindly provided by Jansen 
laboratory, The University of Adelaide). The cells were cultured in minimum essential 
medium supplemented with foetal bovine serum (10% v/v), L-glutamine (2 mM), 
sodium pyruvate (1 mM), penicillin (100 units/ml), and streptomycin (100 μg/ml). The 
cells (4x105) were seeded in a 6-well plate overnight, and a confluent monolayer of cells 
(70-80%) was used for the experiment. The growth medium was removed, and the cells 
were washed twice with PBS and serum free medium, then a serum free medium was 
added for 3 hrs. Stock solutions of CF (carboxyfluorescein) labelled peptides (250 μM) 
in DMSO and water were diluted to give a peptide concentration of 5 μM, and final 
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DMSO concentration of 0.5% in medium. Cells were treated with the peptide and 
incubated for 2 hrs at 37 C. The cells were then washed with ice cold PBS and treated 
1 mg/ml trypsin for 10 minutes to remove any peptide bounded to the surface of the 
cells. After washing with ice cold PBS (x2), the cells were collected by centrifugation 
(1,500xg for 4 minutes). Cellular penetration of the peptides was measured immediately 
using FACS LSRII flow cytometer (BD Bioscience). The fluorescence of viable cells were 
gated and displayed 10,000 events. The data were analysed by using FlowJo Software.  
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